Product EMA FDA EN Other WHO Year Generic DrugBank ID ATC ChEMBL Indications Targets Last Update Abemaciclib Y Y N N 2017 N DB12001 L01EF03 CHEMBL3301610 Advanced Breast Cancer; Metastatic Breast Cancer CDKN2A; PGR; CDK4; ERBB2; CDK6; ESR1; ABCB1; CCND2; NRAS; ESR2; SMARCA4; BRAF; TP53; MKI67; CCND3; CCND1; EIF4EBP1; KRAS; PIK3CA 2024-07-24 Abiraterone Y Y N Y 2011 Y DB05812 L02BX03 CHEMBL254328 Metastatic Castration Resistant Prostate Cancer CYP17A1; CPB2; AR; YBX1; TP53; PTEN; SRD5A2; APC; SRD5A1; TSPYL1; SRD5A3; DSE 2024-07-25 Acalabrutinib Y Y N N 2017 N DB11703 L01EL02 CHEMBL3707348 Chronic Lymphocytic Leukaemia (CLL); Mantle Cell Lymphoma (MCL); Small Lymphocytic Lymphoma EPHB3; FGR; EPHA8; EPHX2; EEGV1; EN1; ENO2; EFNA1; EPS15; DXO; ERBB4; TP53; CYP3A4; BTK; TEC; EFNB2; MS4A2 2024-07-24 Aclarubicin N N N Japan N DB11617 L01DB04 CHEMBL502620 TOP2A; SMN1; CSF2 2024-07-24 Adagrasib N Y N N 2022 N DB15568 L01XX77 CHEMBL4594350 Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer KRAS; GPM6B 2024-07-24 Afamitresgene Autoleucel N Y N N 2024 DB18592 CHEMBL4802254 Unresectable or metastatic synovial sarcoma 2024-10-30 Afatinib Y Y N Y 2013 N DB08916 L01EB03 CHEMBL1173655 Metastatic Non-Small Cell Lung Cancer; Refractory, metastatic squamous cell Non-small cell lung cancer NRG1; BRAF; EGFR; ERBB2; PTEN; ROS1; ERBB3; ALK; NUP62; KEAP1; DVL2; EN1; PIK3CA; ARF1; KRAS; EML4; ERBB4; UHRF1; DXO 2024-07-24 Aflibercept Y Y N N 2011 N DB08885 S01LA05; L01XX44 CHEMBL1742982 Metastatic Colorectal Cancer (MCRC) VEGFA; PIGF; VEGFC; VEGFB; PGF 2024-07-24 Aldesleukin N Y Y N 1992 N DB00041 L03AC01 CHEMBL1201438 High Risk Neuroblastoma; Metastatic Melanoma; Metastatic Renal Cell Carcinoma IL2RA; IL2RB; IL2RG 2024-07-24 Alectinib Y Y N N 2015 N DB11363 L01ED03 CHEMBL1738797 Refractory, metastatic Non small cell lung cancer RET; ALK; ROS1; EML4; TP53; CYP3A4; IDH2; HBEGF; DRD4; BRAF 2024-07-24 Alemtuzumab Y Y N N 2001 N DB00087 L04AA34 CHEMBL1201587 B-Cell Chronic Lymphocytic Leukemia; T-Cell Prolymphocytic Leukemia CD52; TP53; CXCL12 2024-02-07 Alitretinoin Y Y N N 1999 N DB00523 D11AH04; L01XF02 CHEMBL705 AIDS-related Kaposi's Sarcoma RARB; RXRA; RARG; SFTPA1; RXRG; HCN2; RARA; RXRB; ERBB2; BCHE; EHMT2; BCHEL3; GCK; CGA; SERPINE1; CCR2; CD34; BCHEL1; P2RY2; CETP; VDR 2024-07-24 Alpelisib Y Y N N 2019 N DB12015 L01EM03 CHEMBL2396661 Advanced Metastatic Breast Cancer F5; PIK3CB; PIK3CG; BRAF; SGK1; CDK4; PIK3CA; PIK3CD; PIK3R2; PIK3C2A; ERBB2; ESR1; FGFR2; PIK3R1; PI4KA; PIK3R4; F7R; MAP2K1; ESR2; PTEN; FGFR3; PIK3C2B; TP53; PIK3R5; PIK3R6; PIK3R3; FGFR1; PIK3C2G; F7; NRAS; MTOR; ARID1A; PIK3C3; RB1; HRAS 2024-07-24 Altretamine N N Y N 1990 N DB00488 L01XX03 CHEMBL1455 Ovarian Cancer; Ovarian Cancer Stage III CYP1A2 2024-02-07 Aminolevulinic Acid Y Y N N 1999 N DB00855 L01XD04 CHEMBL601 Basal Cell Carcinoma (BCC); Squamous Cell Carcinoma (SCC) BCL2 2024-02-07 Amivantamab Y Y N N 2021 N DB16695 L01FX18 CHEMBL4297774 Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer DRD4; DXO 2024-07-24 Amrubicin N N N Japan N 2002 DB06263 L01DB10 CHEMBL1186894 TOP2A 2024-02-07 Amsacrine N N N N 1987 N DB00276 L01XX01 CHEMBL43 Leukemia, Acute; Refractory Leukemia TOP2A; CYP2C9; TOP2B; CBX1; CYP3A4; EHMT2; ATXN2; CYP2C19; HSD17B10; MTOR; CYP2D6; ATAD5; BTF3P11; DRD1; CYP1A2 2024-07-24 Anastrozole N Y Y Y 1995 Y DB01217 L02BG03 CHEMBL1399 Advanced Breast Cancer; Early Breast Cancer; Locally Advanced Breast Cancer (LABC); Metastatic Breast Cancer; Invasive, early Breast Cancer ESR1; IGF2; PGR; CYP19A1; TUBB1; DLG2; MAP4K4; CLDN11; CSMD1; ERBB2; ZNF613; CYP1B1; CPD 2024-07-24 Apalutamide Y Y N N 2018 N DB11901 L02BB05 CHEMBL3183409 Nonmetastatic Prostate Cancer AR; BEVI 2024-07-24 Arsenic Trioxide Y Y N Y 2018 Y DB01169 L01XX27 CHEMBL1200978 Refractory Acute Promyelocytic Leukemia RARA; SMO; IL6; BIRC5; BDNF; CCND1; TXNRD1; FGFR1; MYCN; SERPINE1; IKBKB; HSPA4; PML; JUN; FLT3; MAPK3; EPO; TERT; FAS; GSTO1; CDKN1A; DNMT1; MT1A; MAPK10; TXNRD2; MAPK1 2024-07-25 Asciminib Y Y N N 2021 N DB12597 L01EA06 CHEMBL4208229 Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase ABL1; BCR 2024-07-24 Asparaginase Y Y N Y 1994 N DB00023 L01XX02 CHEMBL2108989 Acute Lymphoblastic Leukaemias (ALL) ASNS; PYGL; MYBBP1A; PNPLA3; MTHFR; LPL; MIR4268; GATA3; ATF5; HLA-DRB1; GRIA1; MIR3117; TYMSOS; ETV6; CPA2; NFATC2; TYMS; SOD2 2024-07-24 Atezolizumab Y Y N N 2016 N DB11595 L01FF05 CHEMBL3707227 Metastatic Non-Small Cell Lung Cancer; Small Cell Lung Cancer (SCLC); Triple Negative Breast Cancer (TNBC); Urothelial carcinoma ureter metastatic; Locally advanced Urothelial Carcinoma CD274 2024-07-24 Avapritinib Y Y N N 2020 N DB15233 L01EX18 CHEMBL4204794 Metastatic Gastrointestinal Stromal Tumor; Unresectable Gastrointestinal stromal tumor KIT; PDGFRA; FLT3; DPT; CBL 2024-07-24 Avelumab Y Y N N 2017 N DB11945 L01FF04 CHEMBL3833373 Locally advanced disease has progressed during or following platinum-containing chemotherapy urothelial carcinoma (UC); Locally advanced disease has progressed within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy urothelial carcinoma (UC); Metastatic Merkel Cell Carcinoma (MCC); Metastatic disease has progressed during or following platinum-containing chemotherapy urothelial carcinoma (UC); Metastatic disease has progressed within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy urothelial carcinoma (UC) CD274; PMS2; MSH2; MSH6; MLH1; STK11; ATM 2024-07-24 Axicabtagene Ciloleucel Y Y N N 2017 N DB13915 L01XX70 CHEMBL3989989 Refractory Diffuse large B-cell lymphoma NOS; Refractory High grade B-cell lymphoma Burkitt-like lymphoma; Refractory Primary Mediastinal Large B-Cell Lymphoma; Relapsed Diffuse large B-cell lymphoma NOS; Relapsed High grade B-cell lymphoma Burkitt-like lymphoma; Relapsed Primary Mediastinal Large B-Cell Lymphoma CD19 2024-02-07 Axitinib Y Y N N 2012 N DB06626 L01EK01 CHEMBL1289926 Advanced Thyroid cancer KDR; ABCG2; YES1; FLT1; UGT1A9; UGT1A10; DRD2; PDGFRB; PDGFRA; TP53; VHL; ABL1; FABP5; KIT; CD274; PDGFB; HIF1A; UGT1A7; UGT1A8; BRAF; OR2B11; FLT4 2024-07-24 Azacitidine Y Y N N 2004 Y DB00928 L01BC07 CHEMBL1489 Acute Myeloid Leukemia (AML); Chronic Myelomonocytic Leukemia NRAS; DNMT1; TG; MTHFR; ALDH1A1; GMNN; NFE2L2; IDH1; SMAD3; XRCC1; KRAS; TAGLN; FLT3; ATAD5; AFP; GGT1; MYC; ABL1; CDA; MGMT; TP53; AR; IDH2; NR3C1; THPO; LIF; HTT; PLAU; PTPN11; DNMT3A; TYMS; CBL; HBB; GSTP1; CD247; RORC; TRIT1; GATA2; TET2; IL11 2024-07-25 BCG Vaccine Y Y N Y N DB12768 L03AX03 CHEMBL2108905 Non-Invasive Bladder Urothelial Carcinoma; Recurrent Superficial Bladder Cancer; Urothelial Carcinoma Recurrent; Carcinoma in situ of urinary bladder KLK3; IL2; PIK3CB 2024-07-25 Belantamab Mafodotin Y Y N N 2020 N DB15719 L01FX15 CHEMBL4298209 Relapsed Or Refractory Multiple Myeloma ECE1; TUBB; TUBB4A; TUBA1B; TUBA3E; TUBA1C; TUBB2A; TNFRSF17; TUBB2B; TUBB8; TUBA3C; TUBB6; TUBB4B; TUBB3; TUBA4A; TUBA1A; TUBB1 2024-07-24 Belinostat N Y N N 2014 N DB05015 L01XH04 CHEMBL408513 Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-cell Lymphoma Unspecified UGT1A1; HDAC3; HDAC9; HDAC6; HDAC5; HDAC10; HDAC1; FBXW7; HDAC7; GARS1; KMT2A; GAPDHP1; HDAC11; GART; MSTN; GAS1; GDF9; GAS2; GDF2; HDAC4; HDAC8; HDAC2 2024-07-24 Belotecan N N N South Korea N 2003 DB12459 L01CE04 CHEMBL2111084 TOP1 2024-02-07 Belzutifan N Y N N 2023 N DB15463 L01XX74 CHEMBL4585668 Advanced Renal Cell Carcinoma HMGB2 2024-07-24 Bendamustine N Y Y Y 2008 Y DB06769 L01AA09 CHEMBL487253 Chronic Lymphocytic Leukaemia (CLL); Follicular Non-Hodgkin's Lymphoma Refractory; Refractory Hodgkin Lymphoma; Refractory Mantle Cell Lymphoma; Waldenstrom's Macroglobulinemia (WM); Recurrent multiple myeloma; Refractory indolent B cell non-hodgkin lymphoma ATM; TP53; CD69 2024-07-24 Bevacizumab Y Y N Y 2004 N DB00112 S01LA08; L01FG01 CHEMBL1201583 Cervical Cancer Metastatic; Metastatic Colorectal Cancer (MCRC); Metastatic Non-Squamous Non-Small Cell Lung Cancer; Metastatic Renal Cell Carcinoma; Persistent Cervical Cancer; Recurrent Cervical Cancer; Recurrent Glioblastoma; Stage III epithelial ovarian cancer following initial surgical resection; Stage IV epithelial ovarian cancer following initial surgical resection; Fallopian tube cancer following initial surgical resection; Locally advanced nonsquamous non-small cell lung cancer; Primary peritoneal cancer following initial surgical resection; Recurrent Non-Squamous Non-Small Cell Lung Cancer; Recurrent Platinum-Sensitive Epithelial Ovarian Cancer; Recurrent Platinum-resistant Epithelial Ovarian Cancer; Recurrent platinum drug resistant Fallopian tube cancer; Recurrent platinum drug resistant primary peritoneal cancer; Recurrent platinum sensitive primary peritoneal cancer; Recurrent platinum-sensitive fallopian tube cancer; Unresectable Non-Squamous Non-Small-Cell Lung Cancer VHL; CCT3; BRAF; VEGFA; NF2; SLC19A1; SHMT1; HSP90AB1; NF1; GC; KRAS; MMP2; EDN1; ARID1A; MGAT4A; HOXC10; KIT; EGFR; CXCL8; TP53; RALBP1; VEGFB; FOXF1; CSPG4; VEGFC; ANXA11; F2R; EML4; CXCR4; GGH; CD274; PDGFRB; PRKCA; MMP9; ALK; CXCR2; HRAS; PIK3CA; THBS2; IDH1 2024-07-24 Bexarotene Y Y N N 1999 Y DB00307 L01XF03 CHEMBL1023 Refractory peripheral cutaneous T-cell lymphoma NR1I2; OPN1SW; RXRB; RXRG; USP1; HCN2; NR1H3; RXRA; MAPK8; KAT2A; BLM; CCND1 2024-07-24 Bicalutamide N Y Y Y 1995 Y DB01128 L02BB03 CHEMBL409 Stage D2 Prostatic carcinoma CYP2B6; CFLAR; AR; BAX; VDR; KLK3; CDH1; KMT2D; FST; BEVI 2024-07-25 Binimetinib Y Y N N 2018 N DB11967 L01EE03 CHEMBL3187723 Metastatic Melanoma; Unresectable Melanoma BRAF; APC; MAP2K1; ATM; HRAS; NRAS; MAP2K7; UGT1A1; NF1; PTEN; PIK3CA; MAP2K3; KRAS; KIT; MAP2K4; NR2F6; JAK2; MAP2K2; MAP2K6; MAP2K5 2024-07-24 Bleomycin N Y Y Y 1973 Y DB00290 L01DC01 CHEMBL403664 Cervical Cancers; Head and Neck Carcinoma; Intracranial Germ Cell Tumors; Lymphoma, Hodgkins; Malignant Pleural Effusions; Non-Hodgkin's Lymphoma (NHL); Ovarian Cancer; Penile Cancer; Testicular Cancer; Vulvar Cancers; Early Kaposi's sarcoma CCL17; IFNG; NFE2L2; SMAD2; WRN; LIG1; BLMH; F2R; MAPK8; ADK; GSTM1; PLAU; GJA1; CTLA4; BRCA1; AFP 2024-07-24 Blinatumomab Y Y N N 2014 N DB09052 L01FX07 CHEMBL1742992 Precursor B-Lymphoblastic Lymphoma/Leukaemia Refractory; Relapsed B cell precursor Acute lymphoblastic leukemia CD3E; CD19; KMT2A; BCR; CD3D; ABL1; GLRA2; CD247; GMFB; CD3G 2024-07-24 Bortezomib Y Y N Y 2003 Y DB00188 L01XG01 CHEMBL325041 Mantle Cell Lymphoma (MCL); Multiple Myeloma (MM) PSMB11; PSMB4; PSMB10; PSMC3; HSPB2; AR; BDNF; PSMC2; PSMA7; PSMD4; PSMD2; PSMD7; PSMA4; B2M; PSME2; PSMB1; PSMC5; PSMD12; PSMA6; PSMB5; PSMA2; HSPA4; PSMD1; PMAIP1; PIK3CA; PSMB2; PSME1; BCL2L2; PSMD9; PSMD14; PSMA5; PSMC1P1; PSMB6; PSMA1; ADRM1; PSME4; PSMC6; PSMD11; PLG; PSMD8; PSMB8; PSMB3; NFE2L2; PSMB9; PSMB7; F12; PSMC1; FGFR3; FLT3; PSMD6; PSMC4; NFKB1; E2F1; PRSS2; PSME2P2; CCND1; PSMD13; PSMF1; CAPN1; DDIT3; FRA6F; PSME3; F2; PSMD10P1; PSMA8; PSMD5; BCL2; PSMD4P1; PSMC3IP; PRSS3; PSMD10; TP53; PRB2; PSMD10P3; CTSB; PIK3CG; PSMA3; PIPSL; PSMD10P2; GATA2; CTSL; PRSS1; SEM1; PLAT; XIAP; PSMD3 2024-07-25 Bosutinib Y Y N N 2010 N DB06616 L01EA04 CHEMBL288441 Refractory, accelerated phase Chronic myelogenous leukemia; Refractory, blast phase Chronic myelogenous leukemia; Refractory, chronic phase Chronic myelogenous leukemia EPS15; CAMK2G; FBLN2; SRC; CYP2C19; FAU; FGR; BRCA2; ABL1; STK10; BRAF; MS4A2; ENO1P1; STK4; FAUNA@; BCR; LYN; HCK; MEGF6; ENO2; FCGRT; ERVT1; FGF1 2024-07-24 Brentuximab vedotin Y Y N N 2011 N DB08870 L01FX05 CHEMBL1742994 B-large cell anaplastic Lymphoma (Kiel Classification) refractory; Refractory Hodgkin Lymphoma; Post-autologous hematopoietic stem cell transplantation Hodgkin lymphoma TNFRSF8; ALK; TUBA1C; TUBB4B; TUBB3; TUBA3C; TUBB2A; TUBA1A; TUBB8; TUBB2B; TUBA3E; TUBA4A; E4F1; TUBB; TUBA1B; TUBB4A; TUBB1; TUBB6 2024-07-24 Brexucabtagene Autoleucel Y Y N N 2020 N DB15699 L01XL06 CHEMBL4594618 Refractory Mantle Cell Lymphoma; Relapsed Mantle Cell Lymphoma CD19 2024-02-07 Brigatinib Y Y N N 2017 N DB12267 L01ED04 CHEMBL3545311 Metastatic Non-Small Cell Lung Cancer ALK; TP53; DXO; DPH1; EML4; DPEP1; FLT3; ROS1; HBEGF; EGFR; FGFR1 2024-07-24 Buserelin N N Y N 2017 N DB06719 L02AE01 CHEMBL2110824 Stage D2 Prostatic carcinoma GNRHR; IGFBP1 2024-02-07 Busulfan Y Y N N 1954 Y DB01008 L01AB01 CHEMBL820 Essential Thrombocythemia (ET); Polycythemia Vera (PV); Chronic Chronic myelogenous leukemia GSTA1; ADK; ABL1; CYP2C19; ABCC3; MTHFR; THPO; ITGAL; BCR; CYP1A2; GALC; GSTM1; CYP2B6; G6PD; CYP2D6; CYP3A4; GSTP1; CYP2C9; SHBG 2024-07-25 Cabazitaxel Y Y N N 2010 N DB06772 L01CD04 CHEMBL1201748 Refractory, metastatic hormone-refractory Prostate cancer TUBA1A; TUBA1C; TUBB2B; TUBB2A; TUBB6; TUBB4B; TUBB; TUBB1; ABCB1; IGF2; TUBA1B; GCF1; TUBB3; TUBB4A; TUBA3E; TUBA4A; TUBB8; CYP3A4; TUB; CYP2C8; TUBA3C; CYP3A5 2024-07-24 Cabozantinib Y Y N N 2012 N DB08875 L01EX07 CHEMBL2105717 Advanced Renal Cell Carcinoma; Hepatocellular Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Progressive, metastatic Medullary thyroid cancer MET; ROS1; KDR; NRAS; CTNNB1; PTK2B; PBRM1; CFLAR; HGF; KIT; PIK3CA; TP53; HRAS; FLT3; DRD4; DRD2; ABL1; YES1; VHL; GNA11; TEK; RET 2024-07-24 Calaspargase Pegol N Y N N 2018 N DB14730 L01XX86 CHEMBL2108728 Acute Lymphoblastic Leukaemias (ALL) ASRGL1 2024-02-07 Capecitabine Y Y N Y 1998 Y DB01101 L01BC06 CHEMBL1773 Duke's C Colon cancer; Esophageal Cancers; Hepatobiliary Cancers; Malignant Neoplasm of Stomach; Metastatic Breast Cancer; Metastatic Colorectal Carcinoma; Pancreatic Cancer Metastatic; Refractory Fallopian Tube Carcinoma; Metastatic pancreatic endocrine carcinoma; Refractory Ovarian cancer; Refractory peritoneal cancer; Refractory, metastatic Colorectal carcinoma MSH2; REV3L; BRAF; SLC22A7; CYP1A1; UPB1; DPYD; PHC1; CD274; GCGR; CCDC77; VPS13D; AREG; TENM4; TMEM131L; CES1P1; ABCG2; TYMS; SLC19A1; CES1; ADGRG7; ZMIZ1; ATM; ANK3; ERBB2; CDX2; PTGS2; TP53; NCOA7; TYMSOS; CCDC70; SPRY2; UGT1A1; CD96; CYP19A1; SELE; LMNTD1; MGAT4A; MIR2054; FAT1; PTEN; MAN1A1; SIRPA; SSU72; DLG5; EXO1; MSH6; MLH1; PPARD; NSUN3; PIK3CA; KRAS; PMS2; SMAD7 2024-07-25 Capivasertib Y Y N N 2023 N DB12218 L01EX27 CHEMBL2325741 Hormone Receptor-positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer CSTF3; FKBP2; AKT3; AKT2; TP53; ESR1; STK11; PTEN; ERBB2; ESR2; MTOR; CSTP1; PIK3CA; AKT1 2024-07-24 Capmatinib Y Y N N 2020 N DB11791 L01EX17 CHEMBL3188267 Metastatic Non-Small Cell Lung Cancer DRD4; MET; PTEN 2024-07-24 Carboplatin N Y Y Y 1989 Y DB00958 L01XA02 CHEMBL1351 Advanced Cervical Cancer; Advanced Endometrial Cancer; Advanced Esophageal Cancers; Advanced Head and Neck Cancer; Advanced Melanoma; Advanced Non Small Cell Lung Cancer; Advanced Ovarian Carcinoma; Advanced Sarcoma; Metastatic Breast Cancer; Neuroendocrine Carcinoma of the Skin; Pleural mesothelioma malignant; Refractory Hodgkin Lymphoma; Retinoblastoma; Advanced Bladder cancer; Advanced Small cell lung cancer; Advanced Testicular cancer; Advanced Thymoma; Advanced thymic carcinoma; Refractory Non-Hodgkin's lymphoma MUCL3; BIRC5; SCN10A; XRCC1; EGFR; TNF; ADAMTSL4-AS1; ERCC1; BCL2; GCLC; DDX53; PIK3CA; DOCK8; MTHFR; MSH2; MSH6; CD274; RAF1; KRAS; BRCA2; NRG3; HCP5; SLCO1B3; OR4D6; SLC31A1; NR1I2; ERCC2; GSR; ETS2; FGFR1; MLH1; CYP3A5; C6orf15; ATP7A; DSCAM; PPP1R18; ERBB3; TP53; VEGFA; PRRC2A; TRIM5; HLA-C; ATAT1; BRCA1; ALK; EIF4E2; TP73; UGT1A1; PSORS1C1; GSTT1; ATP7B; TIGD1; NF2; GSTP1; POLK; NRAS; MAD1L1; MAP3K1; MSH5; ROS1; MAPT; RNF8; KAT2A; RRM1; PTEN; XYLT2; KEAP1; GPX5; CDSN; HSD17B10; FNTB; NRG1; ALDH1A1; ACSS2; VDR; SLC19A1; ALDH3A1; CDK2; ASS1; SERPINA5; APEX1; CDKN1A; USP1; LIG3; PMS2; ERBB2; SERPINC1; ABCB1 2024-07-24 Carfilzomib Y Y N N 2009 N DB08889 L01XG02 CHEMBL451887 Refractory Multiple Myeloma; Waldenstrom's Macroglobulinemia (WM) PSMD1; PSMB6; PSMD11; PSMA3; PSMD4P1; PSMA6; PSMC1; PSMB2; ADRM1; PSMD4; PSMD8; PSMB7; PSMB5; PSMA8; PSMD13; PSME2; PSMC2; PSMB8; PSMB1; PSMB10; FRA6F; PSMA1; PSMC4; PSMA2; PSMD12; PSMA4; SEM1; PSMC3IP; NFE2L2; PSMD2; VEGFA; PSME3; PSMA5; PSMD3; PSMC5; PSMB11; PSMA7; PSMC3; PIPSL; PSME2P2; PSMB9; PSMB4; PSMD9; PSME4; PRB2; AR; PSMF1; PSMD6; PSMC1P1; PSMD10P3; PSMD10P1; KDR; PSMD10; PSME1; PSMD10P2; PSMC6; PSMB3; PSMD14; PSMD7; PSMD5 2024-07-24 Carmofur N N N Japan N DB09010 L01BC04 CHEMBL460499 CYP3A4 2024-02-07 Carmustine Y Y N N 1977 Y DB00262 L01AD01 CHEMBL513 Astrocytomas; Brain Stem Gliomas; Ependymomas; Glioblastomas; Medulloblastomas; Mycosis Fungoides (MF); Recurrent Glioblastoma Multiforme; Refractory Hodgkin Lymphoma; Refractory Multiple Myeloma; Tumors Metastatic to Brain; High grade newly diagnosed Glioma; Refractory Non-Hodgkin's lymphoma MGMT; ALDH1A1; GSR; CYP2C19; CYP2D6; CYP2C9; PLAU; CYP1A2; G6PD; E2F1; CYP3A4 2024-07-25 Cemiplimab Y Y N N 2018 N DB14707 L01FF06 CHEMBL4297723 Metastatic cutaneous squamous cell carcinoma; Locally advanced cutaneous squamous cell carcinoma, and not a candidate for curative surgery or curative radiation PDCD1; CD274; EGFR; GM2A; ALK; CDK12; ROS1 2024-07-24 Ceritinib Y Y N N 2014 N DB09063 L01ED02 CHEMBL2403108 Refractory, locally advanced Non-small cell lung cancer; Refractory, metastatic Non small cell lung cancer ABCB1; ROS1; DPEP1; ALK; NRAS; DPYS; TSSK1B; FGF12; NPM1; KEAP1; TP53; IGF1R; DPH1; MAP2K1; CYP3A4; HBEGF; EML4; INSR 2024-07-24 Cetuximab Y Y N N 2004 N DB00002 L01FE01 CHEMBL1201577 Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN); Metastatic Colorectal Cancer (MCRC); Metastatic Squamous Cell Carcinoma of the Head and Neck; Recurrent Squamous Cell Carcinoma of the Head or Neck; Regionally Advanced Squamous Cell Carcinoma of the Head and Neck NRAS; TGFA; EGFR; EREG; CTNNB1; KRAS; CXCL8; BRAF; NT5E; BDNF; PIK3CA; EGF; NF2; PTEN; CDKN2A; MGAT4A; BAX; BTC; SMAD4; NRG2; NRG3; ERBB2; HRAS; ERBB3; FCGR3A; VPS37A; AREG; DXO; PTP4A3; MET; HBEGF; TP53; MAP2K1; IDH1; NRG1; GC 2024-07-24 Chlorambucil N Y Y Y 1957 N DB00291 L01AA02 CHEMBL515 Chronic Lymphocytic Leukaemia (CLL); Hodgkins Disease (HD); Non-Hodgkin's Lymphoma (NHL); Waldenstrom's Macroglobulinemia (WM); Giant follicular lymphoma ERBB2; GSTM1; TP53; RORC; FANCC; MGMT; GFER; BAZ2B; NFKB1; CXCL12 2024-07-24 Ciltacabtagene Autoleucel Y Y N N 2022 N DB16738 CHEMBL4802263 Refractory Multiple Myeloma, Relapsed Multiple Myeloma 2024-07-24 Cisplatin N Y Y Y 1978 Y DB00515 L01XA01 CHEMBL2068237 Advanced Pancreatic Cancer; Breast Cancer; Cervical Cancers; Esophageal Cancers; Head and Neck Carcinoma; Hepatobiliary Cancers; Hepatoblastomas; Malignant Neoplasm of Stomach; Medulloblastomas; Metastatic Melanoma; Multiple Myeloma (MM); Neuroblastomas; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer Metastatic; Pleural Mesotheliomas; Primary Central Nervous System Lymphoma (PCNSL); Recurrent Endometrial Cancer; Refractory Hodgkin Lymphoma; Sarcoma, Osteogenic; Small Cell Lung Cancer (SCLC); Thymic Cancer; Advanced Bladder cancer; Metastatic Anal cancer; Metastatic Endometrial cancer; Metastatic Penile cancer; Metastatic Testicular cancer; Refractory Non-Hodgkin's lymphoma CSNK2A3; HEXB; ATM; MLLT3; PPP1R13L; PIK3CA; ERCC4; PLAU; DCBLD1; HMGB1; TPMT; TP53; ERCC1; SYNE3; MECP2; FXN; FGFR1; BAX; ATR; ANPEP; CLCN6; BRCA1; CBX1; BCL2; FANCC; GRP; ERCC6; DFFB; GALNT14; IL6; PRL; GPX5; HPGD; GNAS; TGM2; DDIT3; MGMT; ESR1; MDH2; FASLG; NFE2L2; MPHOSPH8; KDM4E; XIAP; MUTYH; CASP3; CGA; XRCC1; RGS4; TERC; ABCC1; G6PD; CDC25C; GADD45A; ERCC2; FAS; TOP1; KRAS; GSTP1; GSTT1; ATRX; GABPA; GCLM; GCLC; ABCC4; SLC19A1; TYMS; HSD17B10; CYBA; ASS1; LIF; AURKA; ALDH1A1; MTHFD1; FANCA; POLR1G; CD44; MAPT; ALK; ATP7B; EGFR; RB1; SLC22A1; H2AC25; NRAS; APEX1; RECQL; GSTM4; NF2; PPARD; TMEM43; STAT1; OSGEP; GALNT18; DNMT1; BIRC7; MT1H; NR1I2; MAP3K1; RARS1; NHLH1; BRCA2; MDM2; MIR21; EHMT2; IDH1; XRCC3; TP73; SMARCA4; MYCN; CCND1; UBE2I; RAF1; ADH1C; ALOX15; DRAM1; AQP9; HSPA8; ACTL6A; IFNG; E2F1; SEMA6A; KRT20; CDH17; HTR4; MT1F; WFS1; BIRC5; NRG1; RRM1; CHEK1; ABCC5; HSPA4; MSH2; ACSS2; BLMH; CDK12; KAT2A; XRCC5; PTEN; CXCR4; NTRK2; FGFR3; MYC; CD274 2024-07-25 Cladribine Y Y N N 1993 Y DB00242 L04AA40; L01BB04 CHEMBL1619 Chronic Lymphocytic Leukaemia (CLL); Cutaneous T-Cell Lymphoma (CTCL); Hairy Cell Leukemia (HCL); Non-Hodgkin's Lymphoma (NHL) DCK; TP53; XIAP; RRM2B; TGFB1; BCL2L2; RRM1; RRM2; CDKN1A; DIABLO; ADA; YES1; IL2RA; NT5C1A; NFE2L2 2024-07-24 Clofarabine Y Y N N 2004 Y DB00631 L01BB06 CHEMBL1750 Acute Lymphoblastic Leukaemia Recurrent; Refractory Acute Lymphoblastic Leukemia; Refractory Acute Myelogenous Leukemia (AML); Refractory Langerhans cell histiocytosis RRM2; AR; POLA1; POLD2; POLA2; FLT3; POLE2; PRIM1; NIPSNAP2; POLD1; APBB1; GBA1LP; RRM2B; POLD3; POLE3; POLE; PRIM2; POLD4; RRM1 2024-07-24 Cobimetinib Y Y N N 2015 N DB05239 L01EE02 CHEMBL2146883 Metastatic Melanoma; Unresectable Melanoma BRAF; NRAS; MAP2K2; NR2F6; KRAS; CDKN2A; PIK3CA; MAP2K7; CBL; MAP2K5; MAP2K6; MAP2K4; ERCC2; MAP2K1; NF1; RAF1; MAP2K3; ARAF 2024-07-24 Copanlisib N Y N N 2017 N DB12483 L01EM02 CHEMBL3218576 Relapsed Follicular Lymphoma PIK3R2; NRAS; PIK3CG; PIK3R4; PIK3R5; PIK3CD; PIK3CB; PIK3CA; PIK3R3; F7; KIT; PIK3C3; PIK3R6; F7R; PIK3C2A; PTEN; PIK3C2G; AURKB; ETFB; F5; PIK3R1; PIK3C2B 2024-07-24 Crizotinib Y Y N N 2011 N DB08865 L01ED01 CHEMBL601719 Metastatic Non-Small Cell Lung Cancer ROS1; EML4; DRD4; ALK; NPM1; BRAF; MET; ABCB1; KIT; HBEGF; TP53; ERBB2; PIK3CA; JAK2; NTRK1; PTPN12; ABL1; IGF1R; KEAP1; NTRK2; MDM2; KRAS; NTRK3; AREG; HRAS; EGFR 2024-07-24 Cyclophosphamide N Y Y Y 1959 Y DB00531 L01AA01 CHEMBL88 Acute Lymphoblastic Leukaemias (ALL); Acute Myelocytic Leukemia; Adenocarcinoma of the Ovaries; Breast Cancer; Burkitt's Lymphoma; Chronic Lymphocytic Leukaemia (CLL); Chronic Myeloid Leukemia (CML); Disseminated Neuroblastoma; Ewing's Sarcoma; Lung Cancers; Lymphoma, Hodgkins; Multiple Myeloma (MM); Non-Hodgkin's Lymphoma (NHL); Ovarian germ cell tumour; Pheochromocytomas; Retinoblastoma; Rhabdomyosarcomas; Waldenstrom's Macroglobulinemia (WM); Advanced Alibert-Bazin syndrome; Histiocytic lymphoma; Metastatic gestational trophoblastic tumor; Mixed-cell type lymphoma; Refractory Small cell lung cancer; Relapsed Wilm's tumor EHMT2 2024-07-25 Cytarabine Y Y N Y 1969 Y DB00987 L01BC01 CHEMBL803 Acute Lymphocytic Leukemia (ALL); Acute Myeloid Leukemia (AML); Acute Promyelocytic Leukemia (APL); Leptomeningeal Metastases; Meningeal leukemia; Non-Hodgkin's Lymphoma (NHL); Blast phase Chronic myelocytic leukemia ADH1A; IDH2; TP53; CYP3A4; GSTP1; PRIM1; IKZF1; POLA1; HSPA4; KIT; ITGAV; POLD2; GATA3; CCND1; SULT2B1; NQO1; WT1; P2RY12; MSH2; IL1B; EHMT2; TYMSOS; CPT1A; MIR4268; ALK; IGHMBP2; IDH1; CSF2; KMT2A; POLE; NOS3; BIRC5; PRIM2; DOK5; ABCC3; RRM1; CYP2D6; quinone dehydrogenase 2; BMP7; FLT3; TYMS; ATF5; PNPLA3; SLC22A12; NT5C2; POLE2; NRG1; FCGR3A; BRD10; CYP2C9; MIR3117; POLD3; POLA2; SLC29A1; CYP1A2; UGT1A1; VDR; ABCC4; NRAS; RUNX1; RRM2B; POLE3; SLCO1B1; TP73; MED12L; XIAP; FCGR3B; CYP2E1; TPMT; POLD4; NTRK1; CBR3; POLB; MAGEA1; POLD1; NT5C3A; CYP2C19; RRM2; CDA; NCOA3; LINC00251 2024-07-24 Dabrafenib Y Y N N 2013 N DB08912 L01EC02 CHEMBL2028663 Metastatic Melanoma; Unresectable Melanoma; Metastatic Non-small cell lung cancer with a BRAF V600E mutation; Pediatric low-grade glioma (LGG) with a BRAF V600E mutation; Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation NRAS; MAP2K4; MAP2K2; MITF; ALK; HLA-DRB1; HRAS; MAP2K6; PIK3CA; CDKN2A; MAP2K1; G6PD; ATXN1L; EFNA2; AKT1; NF1; RAC1; KRAS; CD274; EML4; MAP2K3; TP53; MAP2K5; MAP2K7; PTEN; BRAF; EZH2 2024-07-24 Dacarbazine N Y Y Y 1975 Y DB00851 L01AX04 CHEMBL476 Advanced Soft Tissue Sarcoma; Lymphoma, Hodgkins; Metastatic Melanoma; Pheochromocytomas; Advanced Medullary thyroid cancer; Advanced Pancreatic neuroendocrine tumor ADK; CYP2C19; CYP1A2; CYP2D6; FN1; CYP2C9; POLA2; MGMT; BAX; CYP1A1; CYP3A4; GSTM1; EPM2AIP1; CXCL8; PLAU 2024-07-25 Dacomitinib Y Y N N 2018 N DB11963 L01EB07 CHEMBL2110732 Metastatic Non-Small Cell Lung Cancer ERBB4; DXO; EN1; ERBB3; EGFR; ERBB2 2024-07-24 Dactinomycin N Y N Y 1964 Y DB00970 L01DA01 CHEMBL1554 Ewing's Sarcoma; Ovarian Cancer; Rhabdomyosarcomas; Sarcoma, Osteogenic; Wilms' tumor; Metastatic nonseminomatous Testicular cancer CEL; NR3C1; MTHFR; VDR; CYP1A2; MTR; TOP2A; EHMT2; NRG1; COIL; RORC; THRB; ESR1; PPARD; NTF3; BGLAP; RECQL; DDIT3; RXRA; TNFRSF8; GRB2; TFPI; CYP3A4; TNFRSF1B; PIK3CB; CYP2D6; CSF1; CD5; ALOX15; AR; AFP; BIRC5; BDNF; APEX1; HTT 2024-07-24 Daratumumab Y Y N N 2015 N DB09331 L01FC01 CHEMBL1743007 Multiple Myeloma (MM); Refractory Multiple Myeloma; Relapsed Multiple Myeloma; Relapsed Or Refractory Multiple Myeloma 2024-07-24 Daratumumab, Hyaluronidase N Y N N 2020 N DB09331 L01FC01 CHEMBL1743007 Multiple Myeloma (MM); Refractory Multiple Myeloma; Relapsed Multiple Myeloma; Relapsed Or Refractory Multiple Myeloma 2024-07-24 Darolutamide Y Y N N 2019 N DB12941 L02BB06 CHEMBL4297185 Non-mestatatic castrate-resistant prostate cancer AR; BEVI 2024-07-24 Dasatinib Y Y N Y 2006 Y DB01254 L01EA02 CHEMBL1421 Acute Lymphoblastic Leukaemias (ALL); Chronic Myeloid Leukemia (CML) TEC; LCK; EPHA2; KIT; ABL2; ACVR1; PDGFRB; PPARD; SRC; LIMK1; HRAS; PLK4; ABL1; PDGFRA; IDH2; FBLN2; KRAS; BTK; IDH1; FYN; FRK; BRCA2; BCR; FES; CBL; KDR; MAP3K20; TET2; LYN; YES1; DDR2; ABCG2; TAOK1; SLK; SYK; MS4A2; JAK2; MAP4K5; CSF3R; SRMS; MAP2K2; AURKB; PIK3CA; IRAK4; FGFR1; PTK6; MAP3K10; NF1; ARID1A; BLK; SMAD3; PKN2; GMNN; SIK2; FAU; ERBB4; APC; ABI1; ABCB1; AR; MAP2K1; MINK1; CSF1R; FAUNA@; ERBB2; CRKL; FGR; STAT5B; MAPK14; ESR1; FGFR3; BRAF; CDC42BPA; HCK; TNK2; AXL; DYRK3 2024-07-24 Daunorubicin N Y Y Y 1979 Y DB00694 L01DB02 CHEMBL178 Acute Lymphocytic Leukemia (ALL); Acute Myeloid Leukemia (AML); Acute Myeloid Leukemia With Myelodysplasia-Related Changes; Acute erythroid leukemia; Acute monocytic leukaemia; Newly diagnosed Therapy-Related Acute Myeloid Leukemia MTHFR; SLC22A7; SLC22A17; TOP2B; KMT2A; MIR4268; IGHMBP2; CYP2J2; MIR3117; ATF5; CPT1A; GPX3; SERPINA6; HTT; POLK; EHMT2; RPSA; AR; WT1; XDH; TOP2A; GATA3; DCK; CDK2; AKR1C3; DOK5; TOP1; THRB; PNPLA3; DNMT3A; TYMSOS; TYMS; ABCC1; BMP7; GSTP1; LINC00251; MAPT; UGT1A1; ABCB1; SLCO1B1; RUNX1; SLC13A3; MAN1B1; APEX1; HDAC4; NOS3; SETD4; HDAC9; GSTA2; IKZF1; HDAC5; ABCG2; HDAC10; HDAC3; APP; CYP1A1; NRP2; NPM1; SLC15A1; ABCA1; SLCO4C1; HDAC1; TPMT; HDAC8; IDH2; ANXA5; AKR1C4; CBR1; HDAC7; KDM4E; CBFB; SLCO6A1; USP1; ABCC9; RECQL; HDAC2; SOD2; AKR7A2; SZRD1; HDAC6; ABCB11; HDAC11; FLT3; GSTM3; COL1A2; FAS; CDA; IDH1; ATP7B; ABCC10; BLM 2024-07-24 Daunorubicin, Cytarabine Liposome Y Y N N 2017 Y DB00694 L01XY01; L01DB02 Acute Lymphocytic Leukemia (ALL); Acute Myeloid Leukemia (AML); Acute Myeloid Leukemia With Myelodysplasia-Related Changes; Acute erythroid leukemia; Acute monocytic leukaemia; Newly diagnosed Therapy-Related Acute Myeloid Leukemia 2021-10-28 Decitabine Y Y N N 2006 Y DB01262 L01BC08 CHEMBL1201129 Chronic Myelomonocytic Leukemia; Myelodysplastic Syndromes (MDS) DNMT3A; CYP27B1; LIF; THBS1; IDH2; KRAS; CDKN2D; TP53; GSTP1; RB1; NR5A1; CDA; GMNN; TGM2; APC; MAGEA1; FLT3; CR2; HLA-E; CCND2; IDH1; CTAG1B; DNMT1; MUC2; IL2RA 2024-07-25 Decitabine , Cedazuridine Y Y N N 2020 N Not found in DrugBank L01BC58 Acute Myeloid Leukaemia 2023-08-01 Degarelix Y Y N N 2008 N DB06699 L02BX02 CHEMBL415606 Advanced Prostate Cancer GNRHR; GNRHR2 2024-07-24 Denileukin Diftitox N Y N N 1999 N DB00004 L01XX29 CHEMBL1201550 Cutaneous T-Cell Lymphoma (CTCL) IL2RG; IL2RB; EEF2; IL12RB1; IL12RB2; IL2RA 2024-07-24 Denosumab Y Y N N 2010 N DB06643 M05BX04 CHEMBL1237023 Giant cell tumor of the bone; Refractory Hypercalcemia of malignancy TNFSF11; TNFRSF11A; BRAF 2024-07-24 Dexamethasone Y Y N Y 1958 Y DB01234 S03BA01; S02BA06; S01CB01; S01BA01; R01AD03; H02AB02; D10AA03; D07XB05; D07AB19; C05AA09; A01AC02 CHEMBL384467 Leukemia, Acute; Malignant Lymphomas; Multiple Myeloma (MM); Mycosis Fungoides (MF) NR3C1; ANXA1; CDK4; CYP2C9; F2RL1; KDR; NRG1; NFE2L2; PTGDR; CHKA; CCL17; RARA; AR; TSC22D3; PZP; DOK5; HSPA8; CDK6; BDM; HTR7; SOAT1; CD86; CARTPT; CRISPLD2; GATA3; SI; CYP2C19; APOB; NR5A1; DPEP1; BMP7; FABP1; RPS19; CYP3A4; CDH17; CHRM3; PYGL; TDO2; CTNNB1; HYAL2; SAG; TYMS; ACTC1; MT1F; GSTP1; TJP1; THRSP; JAK3; S100A10; UBR1; NR1I2; NTRK1; AGTR1; PTH1R; F9; TEAD1; SLC2A4; VEGFA; KRT19; FOLR1; RET; SFTPA1; NPPC; CDK2; SDS; CYP1A2; TGFBR3; BIRC5; VCAM1; GGT1; LIF; IRS2; NR3C2; SERPINE1; IGFBP1; LINC00251; CYP2D6; CHAT; GLS; ALK; UGT1A1; BCL2L11; SMAD3; JUNB; TG; RELA 2024-07-25 Diethylstilbestrol N N Y N 1973 N DB00255 G03CC05; G03CB02; L02AA01 CHEMBL411 BDNF; ESRRB; SLC5A7; GMNN; PTGES3; CYP3A4; AMH; RORC; HRAS; CYP2D6; ESR2; BDKRB2; NPPC; LPO; BDKRB1; CYP1A2; AR; CP; NR1H4; CYP2C19; CYP2C9; NFE2L2; TP53; ERBB2; E2F1; BCYRN1P2; NR1I2; ESRRG; WNT7A; MYC; DNMT1; BCL2; ESR1 2024-07-24 Dinutuximab Y Y N N 2015 N DB09077 L01XC16 CHEMBL3137342 High Risk Neuroblastoma MYCN 2024-02-07 Docetaxel Y Y N Y 1996 Y DB01248 L01CD02 CHEMBL92 Esophageal Cancers; Ewing's Sarcoma; Locally Advanced Breast Cancer (LABC); Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Hormone Refractory Prostate Cancer; Node Positive Breast Cancer; Ovarian Cancer Metastatic; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Advanced untreated gastric adenocarcinoma; Locally advanced Squamous cell carcinoma of head and neck; Locally advanced untreated non small cell lung cancer; Metastatic Squamous cell carcinoma of head and neck; Metastatic untreated non small cell lung cancer; Refractory, locally advanced Non small cell lung cancer; Refractory, metastatic Non small cell lung cancer TUBA1B; ORM2; NR1I2; HRAS; CHST3; XRCC4; TUBB6; TUBA1C; PGR; MUC16; RPL13; CYP1A1; TUBB1; BAX; ABCC6; ATP7A; TUBB; IGF2; ERBB2; SPG7; RAF1; PPCDC; KRAS; SLCO1B1; HNF4A; TUBA3C; FGFR1; STK11; CYP2A6; TUBB8; XRCC3; TUBB2B; ACSS2; TLE3; VAC14; NAT2; BCL2; GCF1; TUB; PTEN; MAP3K1; TUBA4A; PGP; XRCC1; PPARD; KLK3; FOLH1; GSTP1; AKR1C3; TUBB4B; MDM4; ABCG2; TUBB4A; RXRA; TP53; EPHX1; DDIT3; PIK3CA; GSTM1; ADAMTSL4-AS1; PRDX4; RNF8; SULT1C4; ABCC1; CYP4B1; ERBB3; TUBA1A; SNORD68; FGFR3; SLC10A2; ESR2; TUBA3E; FBXW7; ABCC10; BIRC5; NR1I3; TUBB2A; SOD2; CD44; ESR1; GAS6; BRD4; TUBB3 2024-07-24 Dostarlimab Y Y N N 2021 N DB15627 L01FF07 CHEMBL4298124 Adults with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen POLD1; PDCD1; POLE; MLH1; MSH2; PMS2; MSH6 2024-07-24 Doxorubicin N Y Y Y 1974 Y DB00997 L01DB01 CHEMBL53463 Acute Lymphoblastic Leukaemias (ALL); Acute Myeloblastic Leukemia; Advanced Endometrial Cancer; Advanced Soft Tissue Sarcoma; Bladder transitional cell carcinoma; Carcinoma, Bronchogenic; Gastric Carcinoma; Kaposi's Sarcoma AIDS Related; Lymphoma, Hodgkins; Malignant Lymphomas; Metastatic Breast Cancer; Multiple Myeloma (MM); Mycosis Fungoides (MF); Neuroblastomas; Ovarian Cancer Metastatic; Ovarian Carcinoma; Sarcoma, Bone; Sezary Syndrome; Soft Tissue Sarcoma (STS); Thyroid Carcinoma; Waldenstrom's Macroglobulinemia (WM); Wilms' tumor; Advanced Thymoma; Advanced uterine sarcoma ALDH3A1; XIAP; LRP1B; MTHFD1; RARA; BRCA1; PNPLA3; TOP2A; POLK; YWHAG; PAX8; PIK3CB; APEX1; XRCC1; CYP3A4; RXRA; MYOD1; UGT1A1; ABCB11; ZEB1; TET2; CYP2C19; FANCD2; LINC00251; ABCC9; TP53; PIK3CA; AKR7A2; RPSA; TOP2B; MAPK14; SOD2; IL11; HSP90AB1; PIK3CG; WRN; ATM; MGMT; SETD4; CYP2C9; USP1; THRB; RALBP1; RECQL; TPMT; ESR1; SLCO1B1; BDNF; CYP1B1; PLG; EHMT2; IGHMBP2; TGFB1; SRC; MAPK1; CBR1; SDHB; NR1I2; ABCB1; CPT1A; GSTM1; NT5E; SMAD3; HSP90AA1; SLCO6A1; BCL2; COL1A2; BMP7; SERPINA6; AKR1C3; KLC3; SLC22A17; FCGR3B; TAF1; ERCC1; MYB; AR; CAST; NTRK2; ABCC10; NR1H4; CYP1A1; DOK5; GADD45A; XPC; GATA3; BLM; CASP3; ATXN2; ALK; DNMT3A; CYP3A; S100A4; AFP; SLC15A1; MSH2; POLH; GPX3; IDH1; GSR; GBX2; TOP1; NQO1; FASLG; CYP2J2; CYP2D6; BAZ2B; CLCN6; STAT6; ABCA1; PPARD; POLB; SNCA; CCND1; CD274; H2AX; BRAF; CYBA; MDM2; ABCG2; PPM1D; FCGR2A; APAF1; SLC13A3; GALNT14; SLC22A7; SP3; EDN1; MAPT; TGM2; BAX; NFE2L2; CDKN1B; BIRC5; GSTM3; XDH; FLT3; GABPA; ERCC2; CYP1A2; MTR; ABCC5; G6PD; GSTA2; ABCC3; SLCO4C1; FCGR3A; ABCC4; KRT20; KMT2A 2024-07-24 Doxorubicin Liposome Y Y N N 1998 Y Not found in DrugBank L01DB01 CHEMBL53463 Acute Lymphoblastic Leukaemias (ALL); Acute Myeloblastic Leukemia; Advanced Endometrial Cancer; Advanced Soft Tissue Sarcoma; Bladder transitional cell carcinoma; Carcinoma, Bronchogenic; Gastric Carcinoma; Kaposi's Sarcoma AIDS Related; Lymphoma, Hodgkins; Malignant Lymphomas; Metastatic Breast Cancer; Multiple Myeloma (MM); Mycosis Fungoides (MF); Neuroblastomas; Ovarian Cancer Metastatic; Ovarian Carcinoma; Sarcoma, Bone; Sezary Syndrome; Soft Tissue Sarcoma (STS); Thyroid Carcinoma; Waldenstrom's Macroglobulinemia (WM); Wilms' tumor; Advanced Thymoma; Advanced uterine sarcoma ALDH3A1; XIAP; LRP1B; MTHFD1; RARA; BRCA1; PNPLA3; TOP2A; POLK; YWHAG; PAX8; PIK3CB; APEX1; XRCC1; CYP3A4; RXRA; MYOD1; UGT1A1; ABCB11; ZEB1; TET2; CYP2C19; FANCD2; LINC00251; ABCC9; TP53; PIK3CA; AKR7A2; RPSA; TOP2B; MAPK14; SOD2; IL11; HSP90AB1; PIK3CG; WRN; ATM; MGMT; SETD4; CYP2C9; USP1; THRB; RALBP1; RECQL; TPMT; ESR1; SLCO1B1; BDNF; CYP1B1; PLG; EHMT2; IGHMBP2; TGFB1; SRC; MAPK1; CBR1; SDHB; NR1I2; ABCB1; CPT1A; GSTM1; NT5E; SMAD3; HSP90AA1; SLCO6A1; BCL2; COL1A2; BMP7; SERPINA6; AKR1C3; KLC3; SLC22A17; FCGR3B; TAF1; ERCC1; MYB; AR; CAST; NTRK2; ABCC10; NR1H4; CYP1A1; DOK5; GADD45A; XPC; GATA3; BLM; CASP3; ATXN2; ALK; DNMT3A; CYP3A; S100A4; AFP; SLC15A1; MSH2; POLH; GPX3; IDH1; GSR; GBX2; TOP1; NQO1; FASLG; CYP2J2; CYP2D6; BAZ2B; CLCN6; STAT6; ABCA1; PPARD; POLB; SNCA; CCND1; CD274; H2AX; BRAF; CYBA; MDM2; ABCG2; PPM1D; FCGR2A; APAF1; SLC13A3; GALNT14; SLC22A7; SP3; EDN1; MAPT; TGM2; BAX; NFE2L2; CDKN1B; BIRC5; GSTM3; XDH; FLT3; GABPA; ERCC2; CYP1A2; MTR; ABCC5; G6PD; GSTA2; ABCC3; SLCO4C1; FCGR3A; ABCC4; KRT20; KMT2A 2024-07-24 Durvalumab Y Y N N 2017 N DB11714 L01FF03 CHEMBL3301587 Unresectable Stage III Non-small Cell Lung Cancer; Urothelial carcinoma ureter metastatic; Locally advanced Urothelial Carcinoma; Unresectable, locally advanced PD-L1 positive Lung Cancer Non-Small Cell Cancer (NSCLC) MSH2; IDH1; CD274; PMS2; MLH1; ATM; PDCD1; PBRM1; ALK; MSH6; EGFR 2024-07-24 Duvelisib Y Y N N 2018 N DB11952 L01EM04 CHEMBL3039502 Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL); Relapsed or Refractory Follicular Lymphoma; Refractory, relapsed small lymphocytic lymphoma F5; TP53; PIK3CD; PIK3CG; F7; PIK3CB; F7R 2024-07-24 Edotreotide Y N N N 2019 N DB15494 V09IX09 CHEMBL408350 Neuroendocrine Tumors FASLG 2024-07-24 Eflornithine N Y N Y 2023 N DB06243 L01XX79 CHEMBL830 High Risk Neuroblastoma XIAP; JUN; EHMT2; ODC1; NR5A1; TGM2; KCNA1; MYCN; PRL; ATF2; SMOX 2024-07-24 Elacestrant Y Y N N 2023 N DB06374 L02BA04 CHEMBL4297509 Advanced Breast Cancer, Metastatic Breast Cancer ESR1; ERBB2 2024-07-24 Elotuzumab Y Y N N 2015 N DB06317 L01FX08 CHEMBL1743010 Refractory Multiple Myeloma GPR27; SLAMF7 2024-07-24 Elranatamab Y Y N N 2023 N DB15395 L01FX32 CHEMBL4297809 Relapsed or Refractory Multiple Myeloma TNFRSF17; CD3G; CD3D; CD3E 2024-07-24 Emapalumab N Y N N 2018 N DB14724 L04AA39 CHEMBL3989977 IFNG; PRF1; STXBP2; XIAP; SH2D1A; RAB27A; UNC13D; STX11 2024-07-24 Enasidenib N Y N N 2017 N DB13874 L01XX59 CHEMBL3989908 Refractory Acute Myelogenous Leukemia (AML); Relapsed Acute Myelogenous Leukemia (AML) IDH2; FLT3; GRB2; IDH1 2024-07-24 Encorafenib Y Y N N 2018 N DB11718 L01EC03 CHEMBL3301612 Metastatic Melanoma; Unresectable Melanoma KRAS; ARAF; BRAF; RAF1; HRAS; NRAS; TP53; MAP2K1; PTEN 2024-07-24 Enfortumab Vedotin Y Y N N 2021 N DB13007 L01FX13 CHEMBL3301589 Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer NECTIN4 2024-02-07 Entrectinib Y Y N N 2019 N DB11986 L01EX14 CHEMBL1983268 Metastatic Solid Tumors; Non-Small Cell Lung Carcinoma (NSCLC); Tumors, Solid NTRK2; FRK; SYK; NTRK3; FGFR1; BTK; ALK; RET; IGF1R; LYN; STK3; PRKCG; KIT; FLT4; TAOK1; MET; ABL1; AURKB; CAMK1D; NTRK1; SLK; PLK4; MST1R; FLT3; SRC; TNK2; JAK2; CDK7; LRRK2; PKN2; FLT1; ROS1; PRKCQ; AXL; MAP4K5; FGFR3; EML4; MAP4K2; TBK1; RPS6KA3; CLK4; PTK2; LCK; FER; JAK3; CSF1R; BLK; KDR; GRK5; MAP4K4; AURKA; HIPK2; DAPK3; LTK; CLK2; PRKAA1; FYN 2024-07-24 Enzalutamide Y Y N N 2012 N DB08899 L02BB04 CHEMBL1082407 Metastatic Castration Resistant Prostate Cancer BRAF; ATR; ATM; BEVI; CYP17A1; MLH1; PTEN; TP53; CDK12; PIK3CA; APC; BRCA2; AR 2024-07-24 Epcoritamab Y Y N N 2023 N DB16672 L01FX27 CHEMBL4650393 Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-cell Lymphoma (DLBCL) CD3D; CD3G; CD3E; MS4A1 2024-07-24 Epirubicin N Y Y N 1999 Y DB00445 L01DB03 CHEMBL417 Breast Cancer; Breast Cancer Stage II; Breast Cancer Stage III; Colorectal Cancers; Hormone Refractory Prostate Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Papillary transitional cell carcinoma of bladder; Recurrent Superficial Bladder Cancer; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Stomach Tumor; Carcinoma in situ of urinary bladder TUBB2A; HMMR; TYMSOS; FOXO1; PIK3R2; SERPINE1; ABCB1; GCKR; KCNQ1; TOP2A; GNL3; NOS1; SPIDR; TP53; PERP; ERBB2; ABCG2; ABCC2; EPHA6; MDM4; CBR3; INSR; IRS1; BCL2; SLCO1B1; CCNK; BIRC5; MISP; ABCC1; PPP2R5D; FOXP3; RBX1; CHD1; TP53AIP1; SLC28A3; IGF2BP2 2024-07-24 Erdafitinib Y Y N N 2019 N DB12147 L01EN01 CHEMBL3545376 Locally Advanced, Susceptible FGFR3 or FGFR2 genetic alterations, Condition has progressed during or following at least one line of prior platinum- containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy urothelial carcinoma; Metastatic Susceptible FGFR3 or FGFR2 genetic alterations, Condition has progressed during or following at least one line of prior platinum- containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy Metastatic Urothelial Carcinoma SLC26A3; CYP2C9; FGFR3; FGFR1; DPYSL2; DPYSL3; DRD2; FGFR2; PIK3CA; DR1; PTEN; FGFR4 2024-07-24 Eribulin Y Y N N 2010 Y DB08871 L01XX41 CHEMBL1683590 Metastatic Liposarcoma; Refractory, metastatic Breast cancer; Unresectable Liposarcoma TERT; TUBB2A; TUBA3E; TUBA1C; ERBB2; TUBB3; TUBB4A; TUBB1; TUBA3C; CYP3A4; ESR1; GCF1; TUBB4B; TUB; ESR2; TUBA1A; TUBB2B; TUBB; PGR; TUBB8; TUBA4A; TUBB6; CD274; TUBA1B; CDK2 2024-07-25 Erlotinib Y Y N Y 2004 Y DB00530 L01EB02 CHEMBL553 Locally Advanced Non-Small Cell Lung Cancer; Locally Advanced Pancreatic Cancer; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Pancreatic Cancer Metastatic DXO; NF1; EGFR; AURKB; FGFR3; BLK; CBL; LYN; APC; TP53; ALK; ROS1; FLT1; PIK3CA; MET; SYK; YES1; ERBB4; PTEN; BIRC5; PRKD2; CYP1A2; HIPK4; FRK; MINK1; FLT4; DDR2; MAPK1; KRAS; CLK4; ABCB1; CYP3A4; JAK2; ARF1; MKNK2; LTK; CYP3A5; AR; RET; DVL2; NRG1; ABCG2; ABL1; NF2; NUP62; KDR; ERBB3; CYP2D6; FGFR4; UHRF1; PKN2; BRAF; MAP3K1; UGT1A1; IGF1R; SLK; ERRFI1; ERBB2; SLCO2B1 2024-07-25 Estramustine N Y Y N 1981 N DB01196 L01XX11 CHEMBL1575 Metastatic Hormone Refractory Prostate Cancer TDP1; BCL2; BLM; AR; POLK; KAT2A; HEXB; VDR; KLK3; BAX; USP1 2024-07-24 Etoposide N Y Y Y 1983 Y DB00773 L01CB01 CHEMBL44657 Acute Lymphoblastic Leukaemias (ALL); Acute Myeloid Leukemia (AML); Advanced Hodgkin's Lymphoma; Ewing's Sarcoma; Merkel cell cancer; Multiple Myeloma (MM); Neuroblastomas; Neuroendocrine Tumours; Non-Hodgkin's Lymphoma (NHL); Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Prostate Cancer; Retinoblastoma; Sarcoma, Osteogenic; Small Cell Lung Cancer (SCLC); Wilms' tumor; Locally advanced Thymoma; Metastatic Thymic Cancer; Refractory Sarcoma; Refractory Testicular cancer GDF15; SLCO1B1; NCOA3; ITGAL; TOP2A; ALK; MAPK1; PLA2G6; MYCN; ABCC1; ABCC3; TP53; AFP; ATM; CHEK1; CYP2D6; FGFR1; SLC2A4; NTRK3; TNFSF13B; HSPB2; KLK3; TYMS; CYP3A4; GSTT1; TOP2B; TBP; GMNN; NR4A1; PGP; SF3B1; DDIT3; SLIT1; NQO1; BLMH; BCL2; IGF2; BAX; TGFB1; CYP2C19; XIAP; GBX2; PLA2G1B; PAPOLA; NCOA1; GSTM1; DYNC2H1; MUC16; BTF3P11; CYP2C9; UGT1A10; GLP1R; TYMSOS; ACTR2; MAPK3; EIF4E; YAP1; CYP1A2; E2F1 2024-07-24 Everolimus Y Y N N 2009 Y DB01590 L04AA18; L01EG02 CHEMBL1908360 Subependymal giant cell astrocytoma, tuberous sclerosis complex; Advanced Carcinoid tumor; Locally advanced gastrointestinal origin Progressive Neuroendocrine Tumors; Locally advanced lung origin Progressive Neuroendocrine Tumors; Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors; Metastatic lung origin Progressive Neuroendocrine Tumors; Pancreatic origin Progressive Neuroendocrine Tumors; Refractory Advanced Renal Cell Carcinoma; Refractory Waldenstrom's Macroglobulinaemia; Refractory, advanced Breast cancer; Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors; Unresectable lung origin Progressive Neuroendocrine Tumors PIK3CA; ESR1; CDKN2A; FKBP1A; HRAS; FGFR4; FLT3; VHL; TSC1; RPTOR; BRAF; AR; MTOR; PBRM1; TSC2; NRAS; STK11; AKT2; FLCN; ERBB2; AKT3; ARID1A; PTEN; KRAS; CTNNB1; NF2; KDM5C; ATM; BAP1; AKT1; ETFB; PIK3R1; ESR2; NF1; RET 2024-07-25 Exemestane N Y Y N 1999 Y DB00990 L02BG06 CHEMBL1200374 Early Breast Cancer; Refractory, advanced Breast cancer CYP19A1; TCL1A; BGLAP; STK11; ESR1; ESR2; MAP4K4; CYP1B1; PGR; CPD; IGF1R; AKR1C3; NFE2L2; TUBB1; CCDC148; AR; ERBB2 2024-07-24 Fedratinib Y Y N N 2019 N DB12500 L01EJ02 CHEMBL1287853 JAK2; EPHB3; EPHB2; TYK2; EFNA4; FLT3; EPHB1 2024-07-24 Fludarabine N Y Y Y 1991 Y DB01073 L01BB05 CHEMBL1568 B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory; Refractory Non-Hodgkin's lymphoma MPO; NFE2L2; IKZF1; RRM1; POLA1; POLE3; PRIM2; BAX; POLD2; ADH1A; ATM; RRM2B; PIK3CG; POLA2; SLCO1B1; CYP2E1; POLD3; SLC29A1; SMAD3; POLD4; CXCL12; POLD1; POLE; SULT2B1; POLE2; DCK; SLC22A12; XIAP; RRM2; NIPSNAP2; PRIM1; GBA1LP; ADA; CD40 2024-07-24 Fluorouracil N Y Y Y 1962 Y DB00544 L01BC02 CHEMBL185 Breast Cancer; Malignant Neoplasm of Colon; Malignant Neoplasm of Pancreas; Malignant Neoplasm of Stomach; Rectal Carcinoma; Superficial Basal Cell Carcinoma OR10AE3P; PERP; BDNF; GCKR; MECP2; RGS5; GNL3; NOS1; TYMS; FPGS; MUC2; DPYD; FOXO1; FGFR4; ABCC4; REV3L; HSPA5; IL11; CYP19A1; KRAS; CSPG4; PIK3R2; CYP3A4; CD274; ERCC1; LGR5; DLG5; OSGEP; TOP2A; NRAS; FAS; TP53AIP1; IGFBP3; MEGF11; XRCC3; CYP3A; KLC1; WNT5B; ATRX; PPP2R5D; ALCAM; EGFR; BRAF; PTEN; KCNQ1; IL6R; TMEM167A; SLC19A1; EXO1; ATM; CYP2E1; PIK3CA; ABCC1; TSHB; HBB; ITGAL; AURKA; DTYMK; CBR1; MSH6; E2F1; PMS2; ABCC2; ABCB1; CHN2; BIRC5; NT5C1A; RALBP1; CYP4X1; TP53; KLC3; ENOSF1; SELE; SCN1A; SMAD4; TYMP; TYMSOS; IGF2BP2; UPB1; RBX1; TWIST1; ABCC5; FGFR2; PTPRC; TPT1; COLEC10; CBR3; CXCL8; CYP2C8; PARD3B; CDKN1A; CYP2C19; PSMB3P1; MSH2; SLC22A16; DKK1; MLH1; MYB; CYP1B1; PDGFRB; MUTYH; IL2RA; CCNK; INSR; ALDH3A1; IRS1; GALNT14; APEX1; BAX; MAP2K1; GNAS; KEAP1; CYP2A6; HMMR; CCND1; CDC25C; NLGN1; MTHFR; ABCG1 2024-07-25 Fluoxymesterone N Y N N 1956 Y DB01185 G03BA01 CHEMBL1445 Inoperable, metastatic Breast cancer AR; NR3C1; BEVI; PRL 2024-07-24 Flutamide N Y Y N 1989 Y DB00499 L02BB01 CHEMBL806 C Prostatic Carcinoma; Stage B2 Prostatic Carcinoma; Stage D2 Prostatic carcinoma CYP1A2; RORC; KLK3; AR; EHMT2; NFE2L2; CYP3A4; G6PD; TH; VIP; CYP2C19; CYP2C9; NR1I2; BIRC5; PEBP1; MPO; IL2RA; BEVI; AQP9; CDKN1A 2024-07-24 Fotemustine Y N N N DB04106 L01AD05 CHEMBL549386 Metastatic Melanoma MGMT; TXNRD1 2024-02-07 Fruquintinib Y Y N N 2023 N DB11679 L01EK04 CHEMBL4303214 Metastatic Colorectal Cancer KDR; DRD1; FLT1; DRD2; FLT4; DRD3; KRAS 2024-07-24 Fulvestrant Y Y N N 2002 Y DB00947 L02BA03 CHEMBL1358 Advanced or Metastatic Breast Cancer; Refractory, advanced Breast cancer; Refractory, metastatic Breast cancer TP53; PGR; ESR2; ESR1; EML4; NOS1; EPHX2; ESRRA; FGF2; ERBB2; PIK3CA; PIK3CG; TFPI; BCYRN1P2; PTEN; RB1; CYP1A2; FGFR2; CCNE1; CDK6; XIAP; ALK; ALDH3B1; BDNF 2024-07-25 Futibatinib Y Y N N 2022 N DB15149 L01EN04 CHEMBL3701238 Locally Advanced Intrahepatic Cholangiocarcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Unresectable Intrahepatic Cholangiocarcinoma NRAS; FGFR3; FGFR4; SLC26A3; DPYSL2; BRAF; DR1; PIK3CA; FGFR1; FGFR2; DPYSL3 2024-07-24 Gefitinib Y Y N Y 2003 Y DB00317 L01EB01 CHEMBL939 Metastatic Non-Small Cell Lung Cancer PRKD3; EGFR; DXO; HIPK4; MAPK9; TNK2; PLAU; CYP2C9; CHEK2; PHKG2; MET; NUP62; BRAF; FGFR3; BLK; PBK; ERBB3; FRK; IGF1R; MINK1; MAP4K5; ROS1; ERBB4; MAP4K4; LYN; MAPK8; KEAP1; CYP2D6; MAPK14; CRKL; ABCB1; MAPK10; EMP1; SIK2; PRKD2; IRAK4; ALK; CAMK2G; YES1; UHRF1; MAPT; IGF2; PTEN; CAMK2D; SMO; PIM3; ARF1; MAP3K1; SIRT2; HCK; MKNK2; DVL2; LIMK1; PIK3CA; BRSK1; CYP3A5; FLT4; KRAS; ERBB2; LCK; GMNN; CSNK1D; RELA; PIM1; AXL; CEACAM5; SLK; IRAK1 2024-07-24 Gemcitabine N Y Y Y 1996 Y DB00441 L01BC05 CHEMBL888 Advanced Ovarian Cancer; Bladder Transitional Cell Carcinoma Stage IV; Cervical Cancers; Cutaneous T-Cell Lymphoma (CTCL); Head and Neck Carcinoma; Hodgkins Disease (HD); Locally Advanced Pancreatic Adenocarcinoma; Mesothelioma; Metastatic Breast Cancer; Non-Small Cell Lung Cancer Stage IIIB; Non-small Cell Lung Cancer (NSCLC), Stage IV; Non-small Cell Lung Cancer Stage IIIA; Small Cell Lung Cancer (SCLC); Stage 4 Pancreatic adenocarcinoma C6orf15; CYP2C8; NIPSNAP2; ATAT1; AR; WWOX; BRCA2; MDM2; GPX5; SLC29A1; RRM1; POLD1; RAF1; CIP2A; POLE3; TP53; POLD2; POLD4; FKBP5; CHEK1; FANCC; POLD3; CD274; FGFR3; XRCC1; PRIM2; NRAS; POLE2; SERPINC1; POLE; PSORS1C1; TNF; DDX53; NT5C; SERPINA5; RRM2B; BRCA1; PPP1R18; PRB2; CDA; DCP1B; CAMK4; UBASH3B; PRRC2A; MTHFD1; SH2D5; BRAF; PPP1R13L; TNC; OR4D6; DOCK8; PTEN; SLCO1B1; FHL2; IGF2; PPCDC; GBA1LP; ERCC1; RRM2; HCP5; MS4A2; HRAS; ESR2; PIK3CA; SMAD4; POLR1G; MTHFR; ETS2; CDKN2A; CDSN; NT5C1A; SLC29A2; BAZ2B; ACSS2; ALG10; NRG1; MUCL3; HLA-C; WEE1; CDC5L; BTRC; KLC3; XYLT2; MSH5; PRIM1; ALOX5AP; TGM2; CBL; KRAS; TENT4A; ERBB2; POLA2; POLA1 2024-07-24 Gemtuzumab Ozogamicin Y Y N N 2000 N DB00056 L01FX02 CHEMBL1201506 Acute Myeloid Leukemia (AML); Refractory Acute Myelogenous Leukemia (AML); Relapsed Acute Myelogenous Leukemia (AML) CYP2E1; SULT2B1; CD33; CHEK1; SLC22A12; SLCO1B1; ADH1A; PML; GAPDHP60; ABCB1 2024-07-24 Gilteritinib Y Y N N 2018 N DB12141 L01EX13 CHEMBL3301622 Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations HBEGF; AXL; DRD5P1; EML4; KIT; JAK1; CBL; DTNB; DPYS; NRAS; FLT3; ALK; DTNA; DTX1; IDH2; BRAF; JAK3; JAK2; PTK2B 2024-07-24 Glasdegib Y Y N N 2018 N DB11978 L01XJ03 CHEMBL2043437 Acute Myeloid Leukemia (AML) SMO; ALOX12; MTOR; FLT3 2024-07-24 Glofitamab Y Y N N 2023 N DB16371 L01FX28 CHEMBL4298092 Diffuse Large B-Cell Lymphoma (DLBCL), Large B Cell Lymphoma, Primary Mediastinal (Thymic) Large B Cell Lymphoma (PMBCL), Refractory Diffuse Large B Cell Lymphoma (DLBCL), Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Not Otherwise Specified CD3E; MS4A1; CD3G; CD3D 2024-07-24 Goserelin N Y Y N 1989 N DB00014 L02AE03 CHEMBL1201247 Advanced Breast Cancer; Early Breast Cancer; Advanced carcinoma of the prostate; Stage M1 hormone dependent carcinoma of the prostate; Stage T2b carcinoma of the prostate; Stage T2c carcinoma of the prostate; Stage T3 carcinoma of the prostate; Stage T4 carcinoma of the prostate ESR1; LHCGR; MYOD1; GNRHR; SLCO1B1; GNRH1; ESR2; GSR; PGR 2024-07-24 Histamine dihydrochloride Y Y N N 1939 N DB05381 L03AX14 CHEMBL90 Acute Myeloid Leukaemia AMD1; HRH2; UBE2K; HRH3; GLUD1P3; HRH1; EHMT2; AMELX; SLC29A4; HRH4; GAPDH; USP1; LMNA 2024-07-24 Histrelin N Y N N 1991 N DB06788 L02AE05 CHEMBL1201255 Advanced Prostate Cancer GNRHR; GNRHR2 2024-02-07 Hydroxyurea N Y N N 1967 Y DB01005 L01XX05 CHEMBL467 Essential Thrombocythemia (ET); Head and Neck Carcinoma; Melanomas; Ovarian Cancer Metastatic; Polycythemia Vera (PV); Chronic, refractory Myeloid Leukemia; Inoperable Ovarian cancer BLM; PTH; DNMT1; EIF4E; JAK2; TET2; ABL1; MAP3K5; DUSP1; GBA1LP; RRM1; CP; HRAS; ASS1; SIN3A; CYP3A4; NIPSNAP2; KLF4; RRM2B; RRM2; DNTT 2024-07-25 Ibritumomab Tiuxetan Y Y N N 2002 N DB00078 V10XX02 CHEMBL1201606 Follicular Non-Hodgkin's Lymphoma; Follicular Non-Hodgkin's Lymphoma Refractory GATM; MS4A1 2024-07-24 Ibrutinib Y Y N N 2013 N DB09053 L01EL01 CHEMBL1873475 Chronic Lymphocytic Leukaemia (CLL); Mantle Cell Lymphoma (MCL); Waldenstrom's Macroglobulinemia (WM) CSF3R; BTK; ATM; EGFR; PLCG2; EPHX2; EPHB3; FLT3; MS4A2; MYD88; EFNA1; EEGV1; LYN; ERBB2; EPS15; PIM1; FGR; YES1; MYC; EFNB2; EN1; TEC; FKBP1AP3; TP53; CYP2D6; ERBB4; DXO; ENO2; BMX; EPHA8; SMAD3; BLK; ENUR2 2024-07-24 Idarubicin N Y Y N 1990 Y DB01177 L01DB06 CHEMBL1117 Acute Myeloid Leukemia (AML) CBX1; CBR3; CYP2E1; CSF2; POLH; RAPGEF3; FLT3; POLB; SLCO1B1; ETV6; POLI; NQO1; TOP2A; SULT2B1; THRB; ATAD5; FEN1; KCNH2; MPHOSPH8; APEX1; EHMT2; ABCB1; ATXN2; WRN; DRD1; IDH1; MTOR; ERG; PPARD; NT5C3A; HTT; AR; NCF4; USP1; BLM; RECQL; quinone dehydrogenase 2; SLC22A12; DCK; MAPT; BRD10; ADH1A; POLK; RAC2; PLK1; DNMT3A; CYBA; RAPGEF4 2024-07-24 Idecabtagene Vicleucel Y Y N N 2021 N DB16665 L01XL07 CHEMBL4298199 Refractory Multiple Myeloma, Relapsed Multiple Myeloma TNFRSF17 2024-02-07 Idelalisib Y Y N N 2014 N DB09054 L01EM01 CHEMBL2216870 Relapsed Chronic Lymphocytic Leukemia; Relapsed Small Lymphocytic Lymphoma; Relapsed follicular B-cell non-Hodgkin lymphoma PIK3CA; PIK3CD; F5; PIK3CB; BRAF; TP53; PTEN; F7; F7R 2024-07-24 Ifosfamide N Y Y Y 1988 Y DB01181 L01AA06 CHEMBL1024 Cancer, Bladder; Cervical Cancers; Ewing's Sarcoma; Head and Neck Carcinoma; Lymphoma, Hodgkins; Malignant Neoplasm of Pancreas; Non-Hodgkin's Lymphoma (NHL); Ovarian Cancer; Sarcoma, Osteogenic; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Testicular Germ Cell Cancer; Advanced thymic carcinoma TERC; KLC3; IL6; CYP2A6; DNMT1; GSTP1; TP53; ALDH1A1; CYP2B6; ERCC2; ALK; HSPA4; NR1I2; MGMT 2024-07-24 Imatinib Y Y N Y 2001 Y DB00619 L01EA01 CHEMBL941 Chordomas; Chronic Eosinophilic Leukemia (CEL); Chronic Myeloid Leukemia (CML); Desmoid Tumors; FIP1L1-PDGFRa fusion kinase status unknown Chronic eosinophilic leukemia; Metastatic Gastrointestinal Stromal Tumor; Metastatic Melanoma; Myelodysplastic Syndromes (MDS); Refractory Acute Lymphoblastic Leukemia; Metastatic Dermatofibrosarcoma protuberans; Newly diagnosed Acute Lymphoblastic Leukaemia; Newly diagnosed, chronic phase Chronic myeloid leukemia; Recurrent Dermatofibrosarcoma protuberans; Refractory, accelerated phase Chronic myeloid leukemia; Refractory, blast crisis Chronic myeloid leukemia; Refractory, chronic phase Chronic myeloid leukemia; Systemic mastocytosis with associated hematological neoplasm; Unresectable Gastrointestinal stromal tumor KRAS; PDGFRA; CSF1R; ABL1; PDGFB; ABCG2; ABCB1; BCR; PDGFRB; ATIC; RET; FLT3; NTRK1; CTNNB1; HCK; CYP2F1; PIK3CG; PRKCH; IDH1; IKZF1; DUSP1; ABCB4; ABI1; FGF2; CYP2B6; RAD52; ABCC4; BCL2L11; ABL2; IRAK1; EGFR; SMAD3; UGT2A1; XIAP; MYC; FIP1L1; ULK3; JAK2; SLC2A4; SFN; RCSD1; CLK4; BRAF; ABCA3; FRK; SLC19A1; TAOK1; CYP3A5; EYA2; ALK; SYK; CD40LG; NF2; HGF; PVT1; ARID5B; SLCO1A2; YES1; NF1; RUNX1; CSF3R; quinone dehydrogenase 2; DDR1; CD274; PTEN; BIRC5; GSTT1; LCK; CHST1; MAPK10; CYP3A4; DUSP2; LYN; RUNDC3B; KIT 2024-07-25 Imiquimod Y Y N N 1997 Y DB00724 D06BB10 CHEMBL1282 Superficial Basal Cell Carcinoma TLR7; IFNA1; SARDH; GMNN 2024-07-25 Inavolisib N Y N N 2024 DB15275 CHEMBL4650215 Locally advanced or metastatic breast cancer PIK3CG; FGFR2; PIK3CA 2024-11-28 Infigratinib N Y N N 2021 N DB11886 L01EN03 CHEMBL1852688 Unresectable, locally advanced Cholangiocarcinomas, Unresectable, metastatic Cholangiocarcinomas FGFR1; KIT; FGFR3; FGFR4; PIK3R2; PIK3R4; NRAS; DRD2; FGFR2; PIK3C2G; MTOR; SLC26A3; PIK3CB; PIK3CG; PIK3R6; DPYSL2; PIK3CD; PTEN; PIK3C2B; PIK3C3; DR1; PIK3R1; PIK3CA; PIK3R3; PIK3R5; PIK3C2A; DPYSL3 2024-07-24 Inotuzumab Ozogamicin Y Y N N 2017 N DB05889 L01FB01 CHEMBL2108611 Refractory B-cell precursor acute lymphoblastic leukemia; Relapsed B cell precursor Acute lymphoblastic leukemia ABL1; GNG4; CD22; BCR 2024-07-24 Interferon Alfa-2b Y Y N N 1986 N DB00105 L03AB05 CHEMBL1201558 Hairy Cell Leukemia (HCL); Kaposi's sarcoma; Melanoma, Malignant IFNAR1; IFNAR2; ITPA; IL18; TGFB1; IL6; IFNL4; IFNG; IFNA2; TP53; FTO; CSF2; EIF2AK2; BAX 2024-07-24 Iobenguane I-131 N Y N N 1994 N DB06704 V09IX01; V09IX02; V10XA02 CHEMBL1615779 Metastatic Pheochromocytoma; Metastatic Neuroblastoma; Primary Neuroblastomas; Primary Pheochromocytomas; Unresectable, locally advanced iobenguane-scan positive Paraganglioma; Unresectable, locally advanced iobenguane-scan positive Pheochromocytomas; Unresectable, metastatic iobenguane-scan positive Paraganglioma; Unresectable, metastatic iobenguane-scan positive Pheochromocytomas SLC6A2; TH 2024-07-24 Ipilimumab Y Y N N 2011 N DB06186 L01FX04 CHEMBL1789844 Advanced Renal Cell Carcinoma; Cutaneous Melanoma; Hepatocellular Carcinoma; Metastatic Melanoma; Unresectable Melanoma; Metastatic MSI-H/dMMR colorectal cancer NRAS; MLH1; TP53; CD274; GLRB; BRAF; ALK; ATM; PTEN; POLE; POLD1; HLA-A; MSH6; MSH2; MDM2; B2M; PMS2; EGFR; CTLA4; PBRM1 2024-07-24 Irinotecan N Y Y Y 1996 Y DB00762 L01CE02 CHEMBL481 Esophageal Cancers; Ewing's Sarcoma; Glioblastomas; Malignant Neoplasm of Pancreas; Malignant Neoplasm of Stomach; Metastatic Colorectal Carcinoma; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Rhabdomyosarcomas; Small Cell Lung Cancer (SCLC); Recurrent, IV-B Cervical cancer; Recurrent, metastatic Colorectal carcinoma; Refractory, metastatic Pancreatic adenocarcinoma RALBP1; AREG; E2F1; NRAS; UGT1A10; MAPK10; BCHE; TGFB1; TYMSOS; TOP1; BRAF; UGT1A1; ABCC4; KRAS; SYNE3; UGT1A; PIN1; SLCO1B3; AR; CES2; TYMS; ABCG1; CSPG4; ERBB2; SEMA3C; NAT2; XRCC3; TOP1MT; TP53; PIK3CA; RUNX3; GSTM1; CES1; ABCC5; ATM; GSTP1; ABCC1; HSD17B10; FGFR3; MGMT; KLC1; SHMT1; MTHFR; RAD50; UGT1A8; TDP1; DKK1; PDGFRB; RGS5; C8orf34; KCNQ5; BIRC5; UBE2I; ISG15; ALK; PLCB1; PDZRN3; SLC19A1; CDKN1A; TGFBR2; DCBLD1; MAP2K1; CD274 2024-07-24 Irinotecan Liposome Y Y N N 1996 Y DB00762 L01XX19 CHEMBL481 Esophageal Cancers; Ewing's Sarcoma; Glioblastomas; Malignant Neoplasm of Pancreas; Malignant Neoplasm of Stomach; Metastatic Colorectal Carcinoma; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Rhabdomyosarcomas; Small Cell Lung Cancer (SCLC); Recurrent, IV-B Cervical cancer; Recurrent, metastatic Colorectal carcinoma; Refractory, metastatic Pancreatic adenocarcinoma RALBP1; AREG; E2F1; NRAS; UGT1A10; MAPK10; BCHE; TGFB1; TYMSOS; TOP1; BRAF; UGT1A1; ABCC4; KRAS; SYNE3; UGT1A; PIN1; SLCO1B3; AR; CES2; TYMS; ABCG1; CSPG4; ERBB2; SEMA3C; NAT2; XRCC3; TOP1MT; TP53; PIK3CA; RUNX3; GSTM1; CES1; ABCC5; ATM; GSTP1; ABCC1; HSD17B10; FGFR3; MGMT; KLC1; SHMT1; MTHFR; RAD50; UGT1A8; TDP1; DKK1; PDGFRB; RGS5; C8orf34; KCNQ5; BIRC5; UBE2I; ISG15; ALK; PLCB1; PDZRN3; SLC19A1; CDKN1A; TGFBR2; DCBLD1; MAP2K1; CD274 2024-07-24 Isatuximab Y Y N N 2020 N DB14811 L01FC02 CHEMBL3545131 Multiple Myeloma (MM) GMPR 2024-07-24 Ivosidenib Y Y N N 2018 N DB14568 L01XX62 CHEMBL3989958 Newly diagnosed, refractory or relapsed Acute Myeloid Leukemia; Relapsed or refractory Myelodysplastic Syndromes with IDH1 mutation; Locally Advanced or Metastatic Cholangiocarcinoma with IDH1 mutation IDH2; GPX1P2; IDH1 2024-07-24 Ixabepilone N Y N N 2007 N DB04845 L01DC04 CHEMBL1201752 Locally Advanced Breast Cancer (LABC); Metastatic Breast Cancer ESR1; TUBB; ERBB2; TUBA1C; TUBB2B; TUBA3C; TUBB1; TUBA4A; PGR; TUBB8; TUBA1B; TUBB3; TUBA1A; TUBB2A; ESR2; CYP3A4; TUBA3E; TUBB4B; TUBB4A; TUBB6; TUB; GCF1 2024-07-24 Ixazomib Y Y N N 2015 N DB09570 L01XG03 CHEMBL2141296 Multiple Myeloma (MM) PSMD6; PSMC3; PSMD13; PSMB4; PSMA4; PSMB7; PSMC6; PSMA3; PSMD3; PSMB2; PSMA1; FRA6F; PSMD2; SEM1; ADRM1; PSMB3; PSMD4; PSMA2; PSMA5; PSMD8; TP53; PSMB10; PSMB5; PSMA7; PSMD14; PSMC1; PSMC5; PSMD12; PSMA8; PSMD1; ALK; EML4; PSMB6; PSMB8; PSMC2; PSMD11; PSMB1; PSMC4; PSMA6; PSMD7; PSMB11; PSMB9 2024-07-24 Lanreotide N Y Y N 2007 Y DB06791 H01CB03 CHEMBL1201185 Unresectable, locally advanced enteropancreatic neuroendocrine tumors; Unresectable, locally advanced gastroenteropancreatic neuroendocrine tumors; Unresectable, metastatic enteropancreatic neuroendocrine tumors; Unresectable, metastatic gastroenteropancreatic neuroendocrine tumors SSTR2; SSTR5; AQP2; EDN1; SSTR1; SHROOM2; FASLG 2024-07-25 Lapatinib Y Y N N 2007 Y DB01259 L01EH01 CHEMBL554 Metastatic Breast Cancer; Refractory, advanced Breast cancer; Refractory, metastatic Breast cancer RET; EN1; EGFR; ERBB3; YES1; PTEN; ESR1; HLA-A; ERBB2; PIK3CA; ERBB4; PGR; ESR2; BRAF; DXO; CYP3A4; EEF2K; CDKN1B; HLA-B; MET; KRAS; HLA-DRB1; CCND1; AURKB; HLA-C; NRG1; BIRC5; CYP3A5; NF2; ABCB11; HLA-DQA1 2024-07-24 Larotrectinib Y Y N N 2018 N DB14723 L01EX12 CHEMBL3889654 NTRK1 Fusion Positive; NTRK2 Fusion Positive; NTRK3 Fusion Positive NTRK1; NTRK3; NTRK2; DRD5P1 2024-07-24 Lazertinib N Y N N 2024 DB16216 L01EB09 CHEMBL4558324 First-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) EPHB3; DXO; EGFR; DRD2; FDX1 2024-11-28 Lenalidomide Y Y N Y 2005 Y DB00480 L04AX04 CHEMBL848 Chronic Lymphocytic Leukemia (CLL) - Refractory; Follicular Lymphoma (FL); Mantle Cell Lymphoma (MCL); Marginal Zone Lymphoma (MZL); Multiple Myeloma (MM); Myelodysplastic Syndrome; Refractory Diffuse Large B Cell Lymphoma TNFSF11; RBX1; VEGFC; VEGFB; CUL4A; DDB1; KDR; TP53; TNF; CTNNB1; VEGFA; CRBN; FGF2 2024-07-25 Lenvatinib Y Y N N 2015 N DB09078 L01EX08 CHEMBL1289601 Advanced Renal Cell Carcinoma; Locally recurrent radioactive iodine-refractory Thyroid cancer; Metastatic radioactive iodine-refractory Thyroid cancer; Progressive radioactive iodine-refractory Thyroid cancer DRD2; PDGFRB; FLT4; RET; FGFR1; FLT1; KDR; FGFR2; KIT; YES1; PDGFRA; NRAS; CYP3A5; CYP3A4; CYP3A; ABCG2; BRAF; DRD3 2024-07-24 Letrozole N Y Y N 1997 Y DB01006 L02BG04 CHEMBL1444 Advanced Breast Cancer; Early Breast Cancer; Ovarian Epithelial Cancer; Advanced HR + HER2 - breast cancer; Metastatic HR + HER2 - breast cancer CDKN2A; CTNNB1; PGR; ESR1; CYP2A6; SFTPA1; PIK3CA; CPD; RB1; CCDC148; CYP1B1; PTEN; MMP2; CYP3A4; KIT; CYP19A1; ERBB2; ZNF613 2024-07-25 Leuprolide N Y N N 1985 Y DB00007 L02AE51; L02AE02 CHEMBL1201199 Advanced Prostate Cancer CYP2C19; CYP2C9; SMAD3; MMP1; GNRHR; CYP2D6; GNRH1; CYP1A2; AR; CYP3A4 2024-07-24 Lifileucel N Y N N 2024 N DB17107 L01XL11 CHEMBL4298200 Unresectable or metastatic melanoma 2024-04-24 Lisocabtagene Maraleucel Y Y N N 2021 N DB16582 L01XL08 CHEMBL4297236 Grade 3b Follicular Lymphoma; High-grade B-cell Lymphoma (HGBCL); Primary mediastinal large B-cell lymphomas; Refractory Diffuse Large B Cell Lymphoma; Refractory Large B-cell Lymphoma; Relapsed Large B-cell Lymphoma; Relapsed, Diffuse Large B-cell Lymphoma, Relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) CD19 2024-07-31 Lomustine N Y Y N 1976 N DB01206 L01AD02 CHEMBL514 Primary Brain Tumors; Refractory Hodgkin Lymphoma; Tumors Metastatic to Brain IDH1; MGMT; ADK; EGFR 2024-07-24 Loncastuximab Tesirine Y Y N N 2021 N DB16222 L01FX22 CHEMBL4297778 Refractory Large B-cell Lymphoma, Relapsed Large B-cell Lymphoma CD19 2024-02-07 Lorlatinib Y Y N N 2018 N DB12130 L01ED05 CHEMBL3286830 Progressive, metastatic Anaplastic lymphoma kinase-positive Metastatic Non-Small Cell Lung Cancer EML4; ROS1; FGFR1; ENO1; ALK; PIK3CA; NRAS; HRAS; RB1; TP53; BRAF; DTX1; HBEGF 2024-07-24 Lu 177-Dotatate Y Y N N 2018 N DB13985 V10XX04 CHEMBL3989924 Gastroenteropancreatic Neuroendocrine Tumors SSTR1; SSTR5; SSTR3; SSTR2; SSTR4 2024-07-24 Lurbinectedin N Y N N 2020 N DB12674 L01XX69 CHEMBL4297516 Metastatic Small Cell Lung Cancer 2020-09-17 Lutetium Lu 177 Vipivotide Tetraxetan Y Y N N 2022 N DB16778 V10XX05 CHEMBL4594406 Metastatic Castration Resistant Prostate Cancer (CRPC) FOLH1 2024-02-07 Margetuximab N Y N N 2020 N DB14967 L01FD06 CHEMBL2364649 HER2-positive Metastatic Breast Cancer EN1 2024-07-24 Mechlorethamine Y Y N N 1949 N DB00888 L01AA05 CHEMBL427 Carcinoma, Bronchogenic; Chronic Lymphocytic Leukaemia (CLL); Hodgkins Disease (HD); Lymphoma, Diffuse; Mycosis Fungoides (MF); Polycythemia Vera (PV); Stage I Mycosis Fungoides; Malignant effusion MMP2; GSR; GSTP1; CXCR2; NOS1; BAX; ERBB2; MT-CO1; XRCC1; TSHB; CSF2 2024-07-24 Medroxyprogesterone N Y Y N 1959 Y DB00603 G03DA02; G03AC06; L02AB02 CHEMBL717 Metastatic Renal Cell Carcinoma; Metastatic Endometrial carcinoma BAX; PGR; VDR; MMP1; CYP1B1; ESR1; CYP3A5 2024-07-24 Megestrol Acetate N Y Y N 1971 Y DB00351 G03DB02; G03AC05; L02AB01 CHEMBL1201139 Advanced Breast Cancer; Advanced Endometrial Cancer ESR1; ABCB1; AR; PGR; IL2RA; KLK3; NPSR1; IL15; NFE2L2 2024-07-25 Melphalan N Y Y Y 1964 Y DB01042 L01AA03 CHEMBL852 Multiple Myeloma (MM); Ovarian Epithelial Cancer; Severe Hodgkin Lymphoma CTLA4; ABCB1; IFNG; MGMT; RORC; POLR1G; ABL1; SLC7A5; FANCC; NFE2L2; OPLAH; ABCC1; CDKN1A; CDK12; CYP3A4; NR1H4; GSTP1; AR; EHMT2; PLAT; TP53 2024-07-25 Melphalan Flufenamide Y Y N N 2021 N DB16627 L01AA10 CHEMBL4303060 Relapsed Or Refractory Multiple Myeloma CTLA4; ABCB1; IFNG; MGMT; RORC; POLR1G; ABL1; SLC7A5; FANCC; NFE2L2; OPLAH; ABCC1; CDKN1A; CDK12; CYP3A4; NR1H4; GSTP1; AR; EHMT2; PLAT; TP53 2024-07-24 Mercaptopurine Y Y N Y 1953 Y DB01033 L01BB02 CHEMBL1425 Acute Lymphoblastic Leukaemias (ALL); Acute Promyelocytic Leukemia (APL); Lymphoma, Lymphoblastic IDH1; KDM4A; BAZ2B 2024-07-24 Methotrexate Y Y N Y 1953 Y DB00563 L04AX03; L01BA01 CHEMBL34259 Acute Lymphocytic Leukemia (ALL); Acute Promyelocytic Leukemia (APL); Breast Cancer; Cancer, Bladder; Central Nervous System Lymphoma; Choriocarcinoma; Head and Neck Carcinoma; Meningeal leukemia; Sarcoma, Osteogenic; Small Cell Lung Cancer (SCLC); Soft Tissue Sarcoma (STS); Squamous Cell Carcinoma of Lung; Advanced Alibert-Bazin syndrome; Advanced non-Hodgkin lymphoma; Nonleukemic meningeal cancer TYMS; CPT1A; MIR4268; NFATC2; SPECC1L; CDH16; POLB; TNFAIP3; CCND1; GSTM1; ERCC2; NTRK3; GSTT1; ENG; IKZF1; MSH3; CLTC; S100A12; NR1I2; VDR; S100A8; AFP; NQO1; NCOA3; KCNA1; IMPDH1; ADA; HGF; PPARG; NOP2; POLH; NTRK1; GLS; KLRD1; NALCN; FOLH1; CYP2C19; APEX1; CYP2C9; FTCDNL1; DOK5; GATA3; NOS3; PNPLA3; TP53; TLR4; ALOX5; FGFR4; SULT2A1; SLC29A1; HSPB2; SOD2; FLT3; ENOSF1; ICAM3; GSK3B; IDH1; LINC00251; IGHMBP2; SLC22A11; POLI; BIRC5; CYP1A2; FCGR3B; ATF5; SLC28A3; FGF14; HLA-E; BAX; ATP5F1E; KIR2DS4; SLC46A1; BCOR; TARDBP; CDK9; EHMT2; RBMS3; FOLR1; CYP2B6; COL18A1; PYGL; SLAMF1; E2F1; NR3C1; PFDN4; AHRR; KLC3; HSD17B10; MIR3117; SLCO1B1; ATIC; CDH2; CDKN1B; BMP7; CYP2D6; NFATC1; SLC22A8; TAT; DHFR; SLC22A9; ABCC4; FOXP3; CYP3A4; TPM3; ALK; IL2; HLA-C; NFE2L2; SLC16A7; IL1RN; SLC19A1; MPHOSPH8 2024-07-25 Midostaurin Y Y N N 2017 N DB06595 L01EX10 CHEMBL608533 Acute Myeloid Leukemia (AML); Malignant mast cell neoplasm; Systemic mastocytosis with associated hematological neoplasm NTRK3; NPM1; PDGFRA; FLT3; STK32B; JAK3; IL6; IDH2; PRKCQ; KDR; PRKCE; DPYS; JAK2; FGFR3; LATS2; PRKCB; CBL; PRKCH; CTSV; PRKCA; PDGFRB; IL2; PIK3CA; PRKD1; FGFR1; JAK1; PRKCI; PIK3CB; TNF; PRKCG; PRKCD; PRKD3; KIT; PRKCZ; HSPA4; YES1 2024-07-24 Mifamurtide Y N N N 2009 N DB13615 L03AX15 CHEMBL2107354 High-grade, nonmetastatic Osteosarcoma; Resectable, nonmetastatic Osteosarcoma NOD2 2024-02-07 Mirvetuximab Soravtansine Y Y N N 2022 N DB12489 L01FX26 CHEMBL3545132 Platinum Resistant Primary Peritoneal Cancer, Platinum-resistant Epithelial Ovarian Cancer, Platinum drug resistant Fallopian tube cancer HOXB2 2024-07-24 Mitomycin N Y Y N 1981 Y DB00305 L01DC03 CHEMBL105 Adenocarcinoma of the Pancreas; Adenocarcinoma of the Stomach; Breast Cancer; Cancer, Anal; Cancer, Bladder; Cervical Cancers; Head and Neck Carcinoma; Mesothelioma; Non-Small Cell Lung Carcinoma (NSCLC); Low-grade Upper Tract Urothelial Cancer (LG-UTUC) IL1A; PALB2; LGALS2; DHFR; XDH; BRCA1; CYP3A4; CYP1A2; TP53; CYP2C19; AR; CGB5; KRT18; TYMS; VWF; CYP7B1; BGLAP; FANCC; ABCB4; CYP2C9; TAT; MAPK10; CYP2D6; ABCB1 2024-07-25 Mitoxantrone N Y Y N 1987 Y DB01204 L01DB07 CHEMBL58 Acute Lymphocytic Leukemia (ALL); Acute Myeloid Leukemia (AML); Acute Promyelocytic Leukemia (APL); Lymphoma, Hodgkins; Metastatic Breast Cancer; Non-Hodgkin's Lymphoma (NHL); Relapsed Leukemia; Relapsed Lymphomas; Hormone refractory, advanced Prostate cancer; Relapsed Hepatocellular carcinoma UGT1A5; ATAD5; C10orf67; WRN; BRCA1; EHMT2; BLM; DCK; RACGAP1; SLCO1B1; TOP2A; POLH; MAPK1; KDM4A; RPSA; POLI; POLK; ABCG2; RECQL; YES1; MPHOSPH8; ABCB1; HTT; DNMT1; GBX2; TP53; PIM1; FEN1; NSD2; RGS4; BAX; ARSA; NFKB1; ATXN2; RAD52; CBX1; THPO; MECP2; SMAD3; CYP3A4; GALNT14; BCL2; FLT3; MBNL1 2024-07-24 Mobocertinib N Y N N 2021 N DB16390 L01EB10 CHEMBL4650319 Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer EGFR 2024-02-07 Mogamulizumab Y Y N N 2018 N DB12498 L01FX09 CHEMBL1743041 Refractory Mycosis Fungoides/Sezary Syndrome; Relapsed Mycosis Fungoides/Sezary Syndrome CCR4 2024-07-24 Mosunetuzumab Y N N N 2022 N DB15434 L01FX25 CHEMBL4297788 Relapsed follicular lymphoma, Refractory follicular lymphoma MS4A1; CD3D; CD3G; CD3E 2024-07-24 Moxetumomab Pasudotox Y Y N N 2018 N DB12688 L01FB02 CHEMBL1743043 Relapsed/Refractory Hairy Cell Leukemia CD22; GNG4; EEF2 2024-07-24 Nab-Paclitaxel Y Y N N 2005 Y Not found in DrugBank L01CD01 CHEMBL428647 Advanced Cervical Cancer; Advanced Head and Neck Cancer; Advanced Ovarian Cancer; Advanced Soft Tissue Sarcoma; Esophageal Cancers; Fallopian Tube Cancer; Kaposi's sarcoma; Locally Advanced Non-Small Cell Lung Cancer; Malignant Neoplasm of Stomach; Malignant Peritoneal Neoplasm; Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Pancreatic Adenocarcinoma Metastatic; Advanced Bladder cancer; Advanced Thymoma; Metastatic Penile cancer; Refractory Small cell lung cancer; Refractory Testicular germ cell cancer TUBA3E; TRIM5; EPHA6; EPHA5; ROS1; RRM1; TUBB3; TUBB2B; ERCC2; TUBB8; NFE2; MYB; ABCB1; NR1I2; CASP3; KRAS; PTEN; CYP3A; NOP2; ASS1; LIG3; AURKA; TUBB6; CYP3A5; FASN; ABCC2; SOD2; TUBB4A; TUBA1C; FGFR1; PGP; TUBA3C; BCL2; TOP2A; SLCO1B3; TIGD1; FGD4; ABCG2; CBR3; MMP2; FOS; GSTP1; CD274; EIF4EBP1; AFG2A; PDCD4; RAF1; NRG3; STMN1; IL2RA; NAT2; ACSS2; ETS2; JAK2; FNTB; TUBB4B; MSH2; BIRC5; ABCC3; TLE3; ARHGEF10; CXCL8; NBEAP1; CDKN1A; MAP3K1; PMS2; GMNN; FZD3; PIK3CA; TUBA4A; SLC29A1; ERBB2; AR; ABCC1; FCGR2A; ABCC10; MISP; TUBB2A; ATM; SYK; EDNRB; EGFR; GSTM1; DDIT3; CDK2; BRCA1; RB1; EIF4E2; ERCC1; LIF; SLCO1B1; MSH6; SPIDR; GCF1; E2F1; MLH1; TUBA3D; DSCAM; TP53; GSTT1; TUBA1B; TUBB1; MAD1L1; BDNF; NRG1; TUBB; PIK3CG; TUBA1A 2024-07-24 Nab-Sirolimus N Y N N 2021 Y DB00877 L04AH01 CHEMBL413 Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa) TP53; TSC1; PIK3CA; IL10; CTLA4; MTOR; ITGAL; CDKN2A; CRLF2; FBXW7; RHEB; FKBP1A; ABCG2; IL17A; NR1I2; NFE2L2; NF1; PTEN; IL15; ABCB1; PLAU; DCN; AR; PGR; TGM2; STK11; APC; EGFR; MMP1; OPRK1; HRAS; FKBP4; IL7; ALK; FGF2; RB1; EML4; WT1; FLCN; NOS1; RPTOR; IGFBP1; BAX; EIF4E; DDC; DDIT3; NRAS; ADAMTSL4-AS1; TCF7L2; ERBB2; RPS6KB1; PIM1; FGFR1; PRKAA1; MAPK10; RBL2; GAPDHP67 2024-07-25 Nadofaragene Firadenovec N Y N N 2022 N DB17381 L01XL10 CHEMBL3990041 High risk BCG-unresponsive non-muscle invasive bladder cancer IFNA2 2024-02-07 Naxitamab N Y N N 2020 N DB15965 L01FX21 CHEMBL4297984 High risk, refractory Neuroblastomas of the bone or bone marrow; High risk, relapsed Neuroblastomas of the bone or bone marrow 2022-10-23 Necitumumab Y Y N N 2015 N DB09559 L01FE03 CHEMBL1743047 Metastatic Non-Small Cell Lung Cancer EGFR; DXO 2024-07-24 Nelarabine Y Y N N 2005 Y DB01280 L01BB07 CHEMBL1201112 Lymphoblastic lymphoma (Precursor T-lymphoblastic lymphoma/leukemia) refractory; Refractory Acute Lymphoblastic Leukemia POLA1; NT5C2 2024-02-07 Neratinib Y Y N N 2017 N DB11828 L01EH02 CHEMBL180022 Breast Cancer KDR; EN1; EGFR; PGR; ESR2; ERBB4; PIK3CA; CBL; BRAF; HERC2; DXO; ESR1; YES1; ERBB2 2024-07-24 Nilotinib Y Y N Y 2007 N DB04868 L01EA03 CHEMBL255863 Chronic Phase Chronic Myeloid Leukemia; Refractory Gastrointestinal stromal tumor; Refractory, accelerated phase Chronic myeloid leukemia DDR2; ABL1; CYP1A1; PDGFRB; KIT; ABCG2; PDGFRA; BCR; DUSP2; FLT3; GSTP1; CYP3A4; UGT1A1; NF1; ABI1; DUSP1 2024-07-24 Nilutamide N Y N N 1996 Y DB00665 L02BB02 CHEMBL1274 Metastatic Hormone Refractory Prostate Cancer KLK3; AR; CYP2C9; CYP2D6; NFE2L2; CYP2C19; CYP1A2; PRL; BEVI; CYP3A4 2024-07-24 Nintedanib Y Y N N 2014 Y DB09079 L01EX09 CHEMBL502835 Locally advanced Non-Small Cell Lung Cancer (NSCLC) caused by Adenocarcinoma; Locally recurrent Non-Small Cell Lung Cancer (NSCLC) caused by Adenocarcinoma; Metastatic Non-Small Cell Lung Cancer (NSCLC) caused by Adenocarcinoma FGFR2; FGFR3; CFLAR; PIK3CA; PDGFRA; FLT1; KIT; KDR; AKT1; DRD1; DPYSL2; CTSV; DPP4; SLC26A3; DRD3; DPYSL3; FLT4; DSP; DR1; FGFR4; FGFR1; PDGFRB; DRD2; DPP6; RET 2024-07-24 Niraparib Y Y N N 2017 N DB11793 L01XK02 CHEMBL1094636 Fallopian Tube Cancer; Ovarian Epithelial Cancer; Primary Peritoneal Cancer BRCA1; MYCN; BRCA2; PARP1; GNAI2P1; IDH1; PTEN; ARID1A; ATM; GNAI2; CD274; SLFN11; ATR; PARP2 2024-07-24 Nirogacestat Hydrobromide N Y N N 2023 N DB12005 L01XX81 CHEMBL4298153 Progressive Desmoid Tumors PSENEN; NCSTN; APC; NOTCH2; NOTCH3; APP; PSEN1; NOTCH4; GLUL; APH1B; APH1A; PSEN2; CTNNB1; NOTCH1 2024-11-28 Nivolumab Y Y N Y 2015 N DB09035 L01FF01 CHEMBL2108738 Advanced Renal Cell Cancer; Classical Hodgkin's Lymphoma; Hepatocellular Carcinoma; Low Risk Advanced Renal Cell Cancer; Melanomas; Metastatic Colorectal Cancer (MCRC); Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Metastatic Small Cell Lung Cancer; Metastatic Squamous Cell Carcinoma of the Head and Neck; Metastatic Urothelial Carcinoma (UC); Recurrent Head and Neck Squamous Cell Carcinoma; Unresectable Melanoma; Intermediate risk Advanced Renal Cell Cancer; Locally advanced Urothelial Carcinoma FGFR3; CD274; ALK; BRAF; POLE; ATM; PTEN; GM2A; PIK3CA; MLH1; MDM2; PBRM1; EGFR; LAG3; B2M; POLD1; MDM4; ARID1A; MSH2; TP53; IDH1; HLA-DRA; STK11; MSH6; PMS2; NRAS; PDCD1; CDK12; KRAS; ERBB2 2024-07-24 Obinutuzumab Y Y N N 2013 N DB08935 L01FA03 CHEMBL1743048 Refractory Follicular Lymphoma; Previously untreated Chronic lymphocytic leukemia GATM; TP53; MS4A1 2024-07-24 Odronextamab Y N N N 2024 DB16684 CHEMBL4298084 Relapsed/refractory B-Cell non-Hodgkin lymphoma GATM 2024-07-25 Ofatumumab Y Y N N 2009 N DB06650 L04AA52; L01FA02 CHEMBL1201836 Chronic Lymphocytic Leukaemia (CLL); Chronic Lymphocytic Leukemia (CLL) - Refractory; Progressive Chronic Lymphocytic Leukaemia (CLL); Recurrent Chronic Lymphocytic Leukaemia (CLL) MS4A1; GATM 2024-07-24 Olaparib Y Y N N 2014 N DB09074 L01XK01 CHEMBL521686 Fallopian Tube Cancer; Malignant Peritoneal Neoplasm; Metastatic Breast Cancer; Ovarian Epithelial Cancer; Primary Peritoneal Cancer; Advanced deleterious germline or somatic BRCA-mutated advanced epithelial ovarian cancer; Advanced deleterious germline or somatic BRCA-mutated fallopian tube cancer; Advanced deleterious germline or somatic BRCA-mutated peritoneal cancer; Refractory Advanced Ovarian Cancer PPP2R2A; ESR1; PARP1; FFAR1; PGR; BRAF; ESR2; BRCA2; PALB2; STK11; CHEK2; BRCA1; PTEN; DNMT3A; ARID1A; TET2; IDH1; MYC; ATRX; CDK12; TP53; GNAI2P1; IDH2; HDAC2; NRAS; ERBB2; PARP3; PIK3CA; VHL; ATR; KDM6A; MYCN; BAP1; FANCA; FLT3; SF3B1; RAD54L; BARD1; CHEK1; JAK2; GNAI2; PARP2; ATM; MSH3 2024-07-24 Olaratumab Y Y N N 2016 N DB06043 L01FX10 CHEMBL1743049 Soft Tissue Sarcoma (STS) PDGFRA; DPP4 2024-07-24 Olutasidenib N Y N N 2022 N DB16267 CHEMBL4297610 Refractory Acute Myeloid Leukemia (AML), Relapsed Acute Myelogenous Leukemia (AML) IDH1; GPX1P2 2024-07-24 Omacetaxine Mepesuccinate N Y N N 2009 N DB04865 L01XX40 CHEMBL46286 Refractory, accelerated phase Chronic myeloid leukemia; Refractory, chronic phase Chronic myeloid leukemia BIRC5; FLT3; TERT; BCR; ABL1 2024-07-24 Osimertinib Y Y N N 2015 N DB09330 L01EB04 CHEMBL3353410 Metastatic Non-Small Cell Lung Cancer EGFR; STAT3; TP53; KEAP1; ROS1; DXO; PIK3CA; MET; ALK; PTEN; ERBB2; ABCG2; CTNNB1; BRAF; NRAS 2024-07-24 Oxaliplatin N Y Y Y 2002 Y DB00526 L01XA03 CHEMBL414804 Advanced Colorectal Cancer; Advanced Ovarian Cancer; Advanced Pancreatic Cancer; Chronic Lymphocytic Leukemia (CLL) - Refractory; Colon Cancer Stage III; Esophageal Cancers; Malignant Neoplasm of Stomach; Advanced biliary adenocarcinoma; Refractory Neuroendocrine Tumour; Refractory Non-Hodgkin's lymphoma; Refractory Testicular cancer DPYD; GSTP1; PARD3B; GNA13; BCL2; BRAF; BRCA1; ABCC1; CD274; DKK1; FOXC2; FGFR2; MLH1; CXCL10; ATP7A; KRAS; ABL1; ABCC5; KCNQ1; IGF2BP2; TP53; PIN1; MTHFR; GCKR; PMS2; ZEB1; SELE; MSH2; BAX; XRCC3; MSH6; PTEN; ATM; PTGS2; CSMD1; ATP7B; KLC3; MGAT4A; PIK3CA; MT1A; ABCC2 2024-07-25 Paclitaxel Y Y N Y 1992 Y DB01229 L01CD01 CHEMBL428647 Advanced Cervical Cancer; Advanced Head and Neck Cancer; Advanced Ovarian Cancer; Advanced Soft Tissue Sarcoma; Esophageal Cancers; Fallopian Tube Cancer; Kaposi's sarcoma; Locally Advanced Non-Small Cell Lung Cancer; Malignant Neoplasm of Stomach; Malignant Peritoneal Neoplasm; Metastatic Bladder Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma (NSCLC); Ovarian Cancer; Pancreatic Adenocarcinoma Metastatic; Advanced Bladder cancer; Advanced Thymoma; Metastatic Penile cancer; Refractory Small cell lung cancer; Refractory Testicular germ cell cancer TUBA3E; TRIM5; EPHA6; EPHA5; ROS1; RRM1; TUBB3; TUBB2B; ERCC2; TUBB8; NFE2; MYB; ABCB1; NR1I2; CASP3; KRAS; PTEN; CYP3A; NOP2; ASS1; LIG3; AURKA; TUBB6; CYP3A5; FASN; ABCC2; SOD2; TUBB4A; TUBA1C; FGFR1; PGP; TUBA3C; BCL2; TOP2A; SLCO1B3; TIGD1; FGD4; ABCG2; CBR3; MMP2; FOS; GSTP1; CD274; EIF4EBP1; AFG2A; PDCD4; RAF1; NRG3; STMN1; IL2RA; NAT2; ACSS2; ETS2; JAK2; FNTB; TUBB4B; MSH2; BIRC5; ABCC3; TLE3; ARHGEF10; CXCL8; NBEAP1; CDKN1A; MAP3K1; PMS2; GMNN; FZD3; PIK3CA; TUBA4A; SLC29A1; ERBB2; AR; ABCC1; FCGR2A; ABCC10; MISP; TUBB2A; ATM; SYK; EDNRB; EGFR; GSTM1; DDIT3; CDK2; BRCA1; RB1; EIF4E2; ERCC1; LIF; SLCO1B1; MSH6; SPIDR; GCF1; E2F1; MLH1; TUBA3D; DSCAM; TP53; GSTT1; TUBA1B; TUBB1; MAD1L1; BDNF; NRG1; TUBB; PIK3CG; TUBA1A 2024-07-24 Padeliporfin Y N N N 2017 N DB15575 L01XD07 CHEMBL4298112 Low-Risk Prostate Cancer of the one lobe only 2020-09-17 Palbociclib Y Y N N 2015 N DB09073 L01EF01 CHEMBL189963 Advanced Breast Cancer; Metastatic Breast Cancer; Refractory, advanced Breast cancer; Refractory, metastatic Breast cancer MAP4K4; ESR1; CHEK1; LRRK2; CLK2; PIK3CA; CCND2; CCND1; CDK4; MAPK8; PRKAA1; DYRK1B; ERBB2; BRAF; CCND3; TP53; SMARCA4; CDK5; CDK9; CDK6; PGR; CLK4; TAOK1; RB1; PRKD3; CDKN2A; CDKN2B; DAPK3; MAP4K5; DYRK1A; ESR2; KRAS; ROCK2; ALK; MET; PAK4; RPS6KA3; MAPK9; CCNE2; RET; NEK2; NRAS; MAP4K2; CCNE1; EIF4EBP1; PRKX; PTEN; MST1R; FLT3 2024-07-24 Panitumumab Y Y N N 2006 N DB01269 L01FE02 CHEMBL1201827 Metastatic Colorectal Cancer (MCRC) NRAS; NRG2; EGFR; TGFA; CDKN2A; KRAS; AREG; NRG3; MET; TP53; NRG1; PTEN; DXO; PIK3CA; BTC; HBEGF; BRAF; EREG; HRAS; MAP2K1 2024-07-24 Panobinostat Y Y N N 2015 N DB06603 L01XH03 CHEMBL483254 Refractory Multiple Myeloma HDAC1; GDF2; HDAC3; SIRT3; SMARCB1; SIRT1; HDAC2; HDAC8; HDAC9; HDAC4; BRAF; SIRT4; GAPDHP1; MYCN; HDAC10; SIRT2; SIRT5; GARS1; HDAC6; BAP1; CSF1R; HDAC7; SIRT7; ACTL6A; HDAC11; GAS1; HDAC5; SIRT6; GDF9; IDH1; GART; GAS2; KMT2A 2024-07-24 Pazopanib Y Y N N 2009 Y DB06589 L01EX03 CHEMBL477772 Advanced Renal Cell Carcinoma; Advanced Soft Tissue Sarcoma; Advanced Thyroid cancer VHL; KDR; DPYSL2; FGFR1; FGFR2; FLT4; KIT; HFE; PDGFRB; NEK2; HIF1A; TP53; DRD3; ALK; CSF1R; VEGFA; NR1I2; DPYD; NRAS; CDK7; MTOR; LIMK1; ABL1; PDGFRA; AURKA; MAPK9; LCK; DRD2; ITK; MAPK8; UGT1A1; NF1; RET; DRD1; CYP3A4; PBRM1; DPT; AURKB; LTK; MAP4K4; HLA-B; HDAC2; PPARD; TAOK1; DPP6; EWSR1; AR; CYP2C8; PTK2; FYN; SCGB3A1; CXCL8; IGF1R; FLT1; MET; FGFR3; YES1; TNK2 2024-07-25 Pegaspargase Y Y N Y 1994 N DB00059 L01XX24 CHEMBL2108546 Acute Lymphoblastic Leukaemias (ALL) HLA-DRB1; APOC3; HLA-DQA1; TPMT; CPT1A; PNPLA3; UGT1A1; ARHGAP28; BMP7; IGHMBP2; LINC00251; DOK5; GATA3; HLA-DQB1; APOA5 2024-07-24 Peginterferon Alfa-2b Y Y N N 2001 N DB00022 L03AB10 CHEMBL1201561 Melanomas DHODH; IFIT1; IL6; EGFR; JAK2; MICB; HLA-DPA1; CARD16; CTLA4; IFNAR2; CXCL10; OAS1; IFNL3; IFNA2; IL21R; CASP1; IFNAR1; IL18; KLRK1; SLC29A1; VDR; KIR2DS2; SLC6A4; HLA-A; OASL; DNAAF9; SLC28A2; SOCS3; HLA-C; CYP2R1; TUT7; HLA-B 2024-07-24 Pembrolizumab Y Y N Y 2014 N DB09037 L01FF02 CHEMBL3137343 Advanced Renal Cell Carcinoma; Cervical Cancers; Colorectal Cancers; Metastatic Melanoma; Metastatic Solid Tumors; Unresectable Melanoma; Urothelial carcinoma ureter metastatic; Locally advanced Urothelial Carcinoma; Locally advanced gastroesphageal juntion adenocarcinoma; Metastatic gastroesphageal juntion adenocarcinoma; Metastatic nonsquamous non-small cell lung cancer; Recurrent, metastatic Head and Neck Squamous Cell Carcinoma; Refractory, metastatic Non small cell lung cancer; Refractory, relapsed Hodgkin Lymphoma; Refractory, relapsed Mediastinal Large B-cell Lymphoma; Unresectable Solid Tumors ARID1A; EGFR; JAK1; ROS1; POLE; PBRM1; KEAP1; MSH2; PDCD1; MDM4; GM2A; BRAF; FBXW7; JAK2; ERBB2; PDCD1LG2; CD274; MLH1; TP53; PTEN; KIT; KRAS; STK11; MSH6; ALK; IDH1; B2M; POLD1; CDK12; PMS2; NRAS; MDM2; MET; PIK3CA; HLA-DRA 2024-07-24 Pemetrexed Y Y N N 2004 Y DB00642 L01BA04 CHEMBL225072 Mesothelioma; Ovarian Cancer; Pleural Mesotheliomas; Urothelial carcinoma ureter metastatic; Locally advanced nonsquamous non-small cell lung cancer; Metastatic nonsquamous non-small cell lung cancer; Recurrent, IV-B Cervical cancer; Unresectable Thymoma RRM1; CAMKK2; DHFR; EGFR; ALK; TYMS; VEGFA; SLC22A8; ATIC; SLC46A1; GCGR; ROS1; MTHFR; CD274; GART; KRAS; FOLR3; GGH; EXO1; PTEN; MTHFD1; XRCC1; ABCC2; ERCC2; SLC19A1 2024-07-25 Pemigatinib Y Y N N 2020 N DB15102 L01EN02 CHEMBL4297522 Unresectable, locally advanced Cholangiocarcinomas; Unresectable, metastatic Cholangiocarcinomas FGFR3; FGFR2; DPYSL3; DR1; DPYSL2; FGFR1 2024-07-24 Pentostatin N N Y N 1991 Y DB00552 L01XX08 CHEMBL1580 B-Lymphocytic, prolymphocytic leukemia (Kiel Classification) refractory; Chronic Lymphocytic Leukaemia (CLL); Hairy Cell Leukemia (HCL); Mycosis Fungoides (MF); Sezary Syndrome CCR1; PRKAA1; ADA 2024-07-24 Pertuzumab Y Y N N 2012 N DB06366 L01FD02 CHEMBL2007641 Early Breast Cancer; Inflammatory Breast Cancer (IBC); Locally Advanced Breast Cancer (LABC); Metastatic Breast Cancer 2024-07-24 Pertuzumab, Trastuzumab, Hyaluronidase Y Y N N 2020 Not found in DrugBank L01XY02 2021-10-28 Pipobroman N N Y N 1966 DB00236 L01AX02 CHEMBL1585 NFE2L2; KDM4E; ALDH1A1 2024-07-24 Pirarubicin N N N Japan N DB11616 L01DB08 CHEMBL2354444 ABCC1; KMT2A; POLK; MYCN; FEN1; TP53; GLS; HTT; USP1 2024-07-24 Pirtobrutinib Y Y N N 2023 N DB17472 L01EL05 CHEMBL4650485 Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma BTK; TP53; EFNB2; IGH 2024-07-24 Pixantrone Y N N N 2012 N DB06193 L01DB11 CHEMBL167731 Non-Hodgkin's Lymphoma, Relapsed; Refractory Non-Hodgkin's lymphoma TOP2A 2024-02-07 Polatuzumab Vedotin Y Y N N 2019 N DB12240 L01FX14 CHEMBL3301582 Diffuse Large B-Cell Lymphoma (DLBCL) CD79B; TUBB4A; TUBB8; TUBA1B; TUBB4B; BCL6; BCL2; TUBB2A; TUBB; TUBA3E; TUBA1C; TUBB3; TUBB6; TUBB2B; TUBB1; TUBA1A; TUBA3C; MYC; TUBA4A 2024-07-24 Polyestradiol Phosphate N N Y N 1957 DB09369 L02AA02 CHEMBL1201477 ESR1; NOS1; AFP 2024-07-24 Pomalidomide Y Y N N 2013 Y DB08910 L04AX06 CHEMBL43452 Refractory Multiple Myeloma CRBN; RBX1; CUL4A; DDB1 2024-07-24 Ponatinib Y Y N N 2012 N DB08901 L01EA05 CHEMBL1171837 Accelerated phase chronic myologenic leukemia; Acute Lymphoblastic Leukaemias (ALL); Chronic Phase Chronic Myeloid Leukemia; Blast phase Chronic myelocytic leukemia FGFR1; ABL1; FLT3; CDK19; FAP; FGFR3; BCR; PDGFRA; ABL2; FGFR2; KRAS; PDGFRB; ABI1; KIT; EIF4EP1; EML4; FANCG; SRC; PTK2B; RIPK2; YES1; FGFR4; BRAF; KDR; RET 2024-07-24 Porfimer Y Y N N 1995 N DB00707 L01XD01 CHEMBL1201481 Esophageal Cancers; Completely obstructive Non-small cell lung cancer; Microinvasive endobrachial Non-small cell lung cancer; Partially obstructive Non-small cell lung cancer 2020-09-17 Pralatrexate Y Y N N 2009 Y DB06813 L01BA05 CHEMBL1201746 Cutaneous T-Cell Lymphoma (CTCL); Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-cell Lymphoma Unspecified DHFR; PDF; RFC1 2024-07-24 Pralsetinib Y Y N N 2020 N DB15822 L01EX23 CHEMBL4297597 Metastatic RET-fusion Non Small Cell Lung Cancer EML4; HRAS; DRD2; KIF5B; CCDC6; PTK2B; RET 2024-07-24 Prednisolone Y Y N Y 1955 Y DB00860 S03BA02; S02BA03; S01CB02; S01BA04; R01AD02; H02AB06; D07XA02; D07AA03; C05AA04; A07EA01 CHEMBL131 Hypercalcemia of Malignancy; Leukemia, Acute; Malignant Lymphomas; Mycosis Fungoides (MF) LCAT; PNPLA3; CYP3A4; ALPP; NR3C1; DSE; NFE2L2; FCGR3A; FCGR3B; CYBA; MTHFR; TSPYL1; GATA3; AR; RAC2; NR3C2; CYP3A5; BDM; TAT; G6PD; HMGB1; BGLAP; RPS19; CD34; PLG; TG; ANXA1; BAX 2024-07-25 Prednisone N Y Y N 1955 Y DB00635 H02AB07; A07EA03 CHEMBL635 Acute Lymphoblastic Leukaemias (ALL); Aggressive Lymphoma; Hypercalcemia of Malignancy; Leukemia, Acute; Leukemias; Malignant Lymphomas; Metastatic Castration Resistant Prostate Cancer; Mycosis Fungoides (MF) BMP7; TYMS; GSTM1; GSTP1; MIR4268; MC2R; NOS3; DOK5; ITGB2; TG; CXCL12; CYP3A5; CALCA; CYP3A4; VWF; MIR3117; CYP2C9; SLC19A1; TYMSOS; GSTA1; TPMT; IFNG; CYP1A2; GATA3; PTPRC; APOE; LINC00251; NCF4; AR; MYC; MBP; HSD17B10; NR3C1; NFATC1; CTLA4; CYBA; EDNRA; ABCB1; ATF5; BDM; ANXA1; CYP2D6; CYP2C19 2024-07-25 Procarbazine N Y Y Y 1969 N DB01168 L01XB01 CHEMBL1321 Non-Hodgkin's Lymphoma (NHL); Oligodendrogliomas; Primary Central Nervous System Lymphoma (PCNSL); Stage III Hodgkin's Disease; Stage IV Hodgkin's Disease CYP1A2; BAX; EPM2AIP1; CSF2; ALOX15 2024-07-24 Quizartinib Y Y N N 2023 N DB12874 L01EX11 CHEMBL576982 Newly Diagnosed Acute Myeloid Leukemia (AML) DNMT3A; RET; FLT3; DPP6; TET2; DPYD; CSF1R; FGF2; DPYS; PTK2B; DPP4; DPT; KIT; PDGFRB; JAK3; NRAS; PDGFRA; CBL; IDH2 2024-07-24 Racotumomab N N N Cuba, Argentina N DB13045 CHEMBL1743059 2020-09-17 Radium 223 Dichloride Y Y N N 2013 N DB08913 V10XX03 CHEMBL2107816 Castration resistant, metastatic Prostate cancer 2020-09-17 Raltitrexed N N Y Canada N 1996 N DB00293 L01BA03 CHEMBL225071 Advanced Colorectal Cancer; Pleural Mesotheliomas CDK2; TYMS; CDKN1B; SLC19A1; ALB; GCGR; DHFR 2024-07-24 Ramucirumab Y Y N N 2014 N DB05578 L01FG02 CHEMBL1743062 Advanced Gastric Cancer; Advanced gastro-esophageal junction adenocarcinoma; Refractory, metastatic Colorectal cancer; Refractory, metastatic Non small cell lung cancer KDR; PDGFRA; EGFR; KRAS; DRD2; ALK 2024-07-24 Ranimustine N N N Japan N DB13832 L01AD07 CHEMBL2105348 2020-09-22 Realgar-Indigo Naturalis Formulation N N N China Y 2009 Not found in DrugBank L01XX27 Acute promyelocytic leukaemia 2021-03-10 Regorafenib Y Y N N 2012 N DB08896 L01EX05 CHEMBL1946170 Hepatocellular Carcinoma; Metastatic Colorectal Cancer (MCRC); Metastatic Gastrointestinal Stromal Tumor; Locally advanced Gastrointestinal stromal tumor; Unresectable Gastrointestinal stromal tumor PDGFRA; MAP2K1; FGFR2; NTRK1; EPHA2; DDR2; VHL; ABL1; KDR; ZHX2; KIT; FGFR3; KRAS; RET; VEGFA; BRAF; FGFR1; FRK; ARAF; EFNA2; PTEN; DRD2; PIK3CA; FBXW7; NRAS; YES1; TEK; EGFR; MAPK11; FLT1; PDGFRB; RAF1; FLT4 2024-07-24 Relatlimab , Nivolumab Y Y N N 2022 DB14851 L01XY03 CHEMBL3990044; CHEMBL2108738 Metastatic Melanoma, Unresectable Melanoma 2024-07-25 Relugolix Y Y N N 2020 N DB11853 L02BX04 CHEMBL1800159 Advanced Prostate Cancer GNRHR; LHCGR 2024-02-07 Repotrectinib N Y N N 2023 N DB16826 L01EX28 CHEMBL4298138 locally active or metastatic non-small cell lung cancer EML4; NTRK3; ALK; ROS1; DTX1; NTRK1; DRG2; EPHB2; DRD5P2; HBEGF; DRD5P1 2024-07-24 Retifanlimab Y Y N N 2023 N DB15766 L01FF10 CHEMBL4298037 Metastatic Locally Advanced Merkel Cell Carcinoma, Recurrent, locally advanced Merkel Cell Carcinoma GM2A 2024-07-24 Ribociclib Y Y N N 2017 N DB11730 L01EF02 CHEMBL3545110 Advanced Breast Cancer; Metastatic Breast Cancer CDK4; PIK3CA; PGR; CCND3; ALK; RB1; JAK2; ERBB2; ESR1; NRAS; CCND1; CCND2; SMARCA4; BRAF; CDK6; ESR2; PTEN; CDKN2A 2024-07-24 Ripretinib Y Y N N 2020 N DB14840 L01EX19 CHEMBL4216467 Advanced Gastrointestinal Stromal Tumor (GIST) CYP3A4; KIT; PDGFRB; PDGFRA; DPT 2024-07-24 Rituximab Y Y N Y 1997 N DB00073 L01FA01 CHEMBL1201576 Chronic Lymphocytic Leukaemia (CLL); Non-Hodgkin's Lymphoma (NHL) ABCB1; ERBB2; TET2; MS4A1; KRAS; FCGR3A; CYBA; ARID1A; IFNG; IL2; NCF4; GATM; CD274; RPS19; PIK3CA; TGFB1; CD38; EGFR; EN1; GMPR; JAK2; PIK3CG; PGR; EPCAM; NRG1; CBR3; PPCDC; IL6; MET; ANXA1; TP53; FCGR2A; GSTA1; HSPB2; CXCL12; AKT2; XIAP; RNF8; HGF; ESR1; ERBB3; CXCL13; PTEN; BIRC5; ESR2 2024-07-24 Rituximab, Hyaluronidase N Y N N 1997 N DB00073 L01XC02 CHEMBL1201576 Chronic Lymphocytic Leukaemia (CLL); Non-Hodgkin's Lymphoma (NHL) ABCB1; ERBB2; TET2; MS4A1; KRAS; FCGR3A; CYBA; ARID1A; IFNG; IL2; NCF4; GATM; CD274; RPS19; PIK3CA; TGFB1; CD38; EGFR; EN1; GMPR; JAK2; PIK3CG; PGR; EPCAM; NRG1; CBR3; PPCDC; IL6; MET; ANXA1; TP53; FCGR2A; GSTA1; HSPB2; CXCL12; AKT2; XIAP; RNF8; HGF; ESR1; ERBB3; CXCL13; PTEN; BIRC5; ESR2 2024-07-24 Romidepsin Y Y N N 2009 Y DB06176 L01XH02 CHEMBL343448 Refractory peripheral cutaneous T-cell lymphoma BRAF; HDAC1; HDAC10; CDKN2D; HDAC5; GDF2; HDAC4; GAS2; HDAC6; ADAMTSL4-AS1; HDAC2; GDF9; ERBB2; KMT2A; GART; MSTN; GAPDHP1; HDAC8; HDAC9; ABCB1; GAS1; GARS1; CDKN1A; CTAG1B; HDAC3; HDAC11; BIRC5; HDAC7 2024-07-24 Rucaparib Y Y N N 2016 N DB12332 L01XK03 CHEMBL1173055 Advanced Ovarian Cancer PARP2; PARP1; PRKD2; BRCA1; CDK12; ATM; CDK1; IDH1; PALB2; CYP2D6; NRAS; DYRK1A; ARID1A; CYP1A2; ATR; PIM1; PTEN; YES1; BRCA2; BRAF; PARP3; GNAI2 2024-07-24 Ruxolitinib Y Y N N 2011 N DB08877 L01EJ01 CHEMBL1789941 Post Polycythemia Vera Myelofibrosis; Refractory Polycythemia vera JAK2; SH2B3; CSF3R; JAK3; JAK1; PLAUR; VHL; CRLF2; EPHB3; EPHB2; BRAF; CYP3A4; EPHB1; TYK2; IL7R; TP53; FLT3 2024-07-24 Sacituzumab Govitecan Y Y N N 2020 N DB12893 L01FX17 CHEMBL3545262 Metastatic Triple-negative Breast Cancer ESR2; BRCA1; UGT1A1; ESR1; TOP1; UTS2R; TACSTD2; ERBB2; BRCA2 2024-07-24 Selinexor Y Y N N 2019 N DB11942 L01XX66 CHEMBL3545185 Refractory Multiple Myeloma FLT3; TET2; TP53; XPO1; H2AX 2024-07-24 Selpercatinib Y Y N N 2020 N DB15685 L01EX22 CHEMBL4559134 Advanced RET-fusion thyroid cancer; Advanced RET-mutant medullary thyroid cancer; Metastatic RET-fusion Non Small Cell Lung Cancer; Metastatic RET-fusion thyroid cancer; Metastatic RET-mutant medullary thyroid cancer RET; KIF5B; PTK2B; CCDC6 2024-07-24 Sipuleucel-T N Y N N 2010 N DB06688 L03AX17 CHEMBL1237024 Asymptomatic, metastatic hormone-refractory Prostate cancer; Minimally symptomatic, metastatic hormone-refractory Prostate cancer ACP3 2024-02-07 Sonidegib Y Y N N 2015 N DB09143 L01XJ02 CHEMBL2105737 Refractory, locally advanced Basal cell carcinoma PTCH1; SMO; ALOX12; SUFU; FLT3; MYCN 2024-07-24 Sorafenib Y Y N N 2005 Y DB00398 L01EX02 CHEMBL1336 Advanced Renal Cell Carcinoma; Gastrointestinal Stromal Tumors; Hemangiosarcoma; Unresectable Hepatocellular Carcinoma; Locally recurrent refractory to radioactive iodine treatment Thyroid carcinoma; Metastatic refractory to radioactive iodine treatment Thyroid carcinoma DPP6; RAF1; BRAF; CDK19; PLK4; KDR; FLT3; FLT4; RET; MAPK13; ARID1A; VEGFB; SLK; PRKCE; KIT; PDGFRB; MC4R; MAPK14; CAMK2B; KRAS; DYRK3; JAK3; NRAS; MAP3K20; ABCC2; MAP2K6; FGFR1; MAPK4; ARAF; HIPK4; FLT1; ATXN2; PDGFRA; MAP2K1; MAPK10; ABCB1; VEGFC; EFNA2; TP53; EGFR; MAPK11; FGFR3; CSF1R; MAPK12; VHL; DPT; FAH; JAK1; RPS6KB1; TAOK1; DPYS; SLC22A1; SRPK1; NTRK1; AURKB; ZHX2; ADAMTS18; MAPK6; MAPK3; LIMK1; AURKA; HIF1A; MAPK8; PIK3CA; NR1I2; ABL1; VEGFA; IDH2; TNF; BLK; AR; CTNNB1; NFE2L2; ABCG2; WWOX; NOS3; CYP2C9; HMOX1; NTRK2; CYP3A4; PTPN6; PAX8; CDH13; SLC15A2; NTRK3; CDK8; DUSP2; UGT1A9; GMNN; IRAK1; DPYSL2; PTK2B; CBL; SLCO1B1; MAPK1; MKNK2; NF1; DRD2; YES1; NTSR1; HIPK2; MAP4K5; EIF4EP1; AXL; MINK1; CYP2C8; MAPK9; CYP2B6; PTEN; EPHA2; FGF3; FGF2; LYN; MAPK7 2024-07-24 Sotorasib Y Y N N 2021 N DB15569 L01XX73 CHEMBL4535757 Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer KRAS; HRAS; NRAS 2024-07-24 Streptozocin N Y N N 2005 N DB00428 L01AD04 CHEMBL1651906 Stage 4 islet cell carcinoma SI; IGFBP1; DDIT3; S100B; SSTR1; CYP7B1; CSF2; TRPV1; TH; CTSD; PTGER4; HRAS; OGA; TGFB1; THRSP; SULT1A2; CD40; BCL2; ATF2; ADCYAP1; CDKN1B; ACP5; GALP; CYP2D6; VWF; KCNJ11; UCP1; LCAT; HGF; SLC2A4; SLC5A1; RAMP3; KCNA2; MT1H; NTRK1; HP; MMP2; PRKAA1; SLC2A5; SFTPB; SST; PREP; MYO9B; ENO2; PIK3CA; SLC16A3 2024-07-24 Sugemalimab Y N N N 2024 DB16641 L01FF11 CHEMBL4594535 Metastatic non-small cell lung cancer (NSCLC) CD274 2024-11-28 Sunitinib Y Y N N 2006 Y DB01268 L01EX01 CHEMBL535 Advanced Renal Cell Carcinoma; Soft Tissue Sarcoma (STS); Thyroid Cancers; Metastatic Pancreatic Neuroendocrine Tumors; Refractory Gastrointestinal stromal tumor; Unresectable, locally advanced Pancreatic Neuroendocrine Tumors FLT1; PDGFRA; DPT; IL4R; KDR; KIT; DPP6; PDGFRB; RET; PDGFB; BAP1; PDGFA; NOS3; VHL; PTPN12; PDGFD; TP53; NR1I2; FGFR2; SLCO1B3; DPYSL2; FLT4; VEGFC; PDGFC; POR; FLT3; CSF1R; CA9; CTSV; DRD3; EWSR1; PTPRB; HIF1A; PTEN; CXCL8; LATS2; DPYS; MKI67; KDM5C; DRD2; YES1; NR1I3; CYP3A4; VEGFA; SLC22A5; FGFR1; PBRM1; PTK2B; HMOX1 2024-07-25 Tafasitamab Y Y N N 2020 N DB15044 L01FX12 CHEMBL4298047 Refractory Diffuse large B-cell lymphoma NOS; Relapsed Diffuse large B-cell lymphoma NOS GMFB; TNFRSF8; CD19 2024-07-24 Tagraxofusp Y Y N N 2018 N DB14731 L01XX67 CHEMBL4297573 Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) CSF2RB; EEF2; IL3RA 2024-07-24 Talazoparib Y Y N N 2018 N DB11760 L01XK04 CHEMBL3137320 Locally Advanced Breast Cancer (LABC); Metastatic Breast Cancer MYCN; CDK12; MLH1; STK11; BRCA2; FLT3; SLFN11; PARP2; ATRX; GNAI2; ATR; BRAF; GNAI2P1; PSMD4; PARP1; NRAS; ARID1A; IDH1; EGFR; DNMT3A; ERBB2; IDH2; ATM; BRCA1; TET2; PALB2; PTEN 2024-07-24 Talimogene Laherparepvec Y Y N N 2015 N DB13896 L01XX51 CHEMBL2108727 Unresectable Skin Lesion CSF2; CSF2RA 2024-07-24 Talquetamab Y Y N N 2023 N DB16678 L01FX29 CHEMBL4594503 Relapsed and Refractory Multiple Myeloma CD3G; GPRC5D; CD3E; CD3D 2024-07-24 Tamoxifen N Y Y Y 1977 Y DB00675 L02BA01 CHEMBL83 Breast Cancer; Desmoid Tumors; Endometrial Cancer; Invasive Breast Cancer; Invasive Breast Carcinoma; Metastatic Breast Cancer; Ovarian Cancer AURKA; ESR1; PGR; FMO3; ATXN2; ESR2; HSPB2; COL18A1; VDR; HEXB; PLD1; EHMT2; CYP2C9; MUC16; ERBB2; RRAS2; SLCO1A2; NFE2L2; NCOA3; NF1; TFF3; CYP2B6; CYP2D6; TP53; FMO1; CYP19A1; EDN1; PLD2; PIP; ZNF613; F2; E2F7; BRCA1; LRMDA; NR1I2; BAZ2B; ALDH3B1; CBX1; GGT1; GMNN; CCND1; MYOD1; DHFR; CYP1A2; SLCO2B1; KLK3; PIK3CA; UGT1A4; BCYRN1P2; NCOA1; NRG1; CETP; CYP3A4; ZNF423; CCNA2; TGM2; IGF1R; IDH1; NTRK1; GAPDH; KDM4A; BGLAP; TYMS; F5; TGFB1 2024-07-24 Tarlatamab N Y N N 2024 N DB17256 L01FX33 CHEMBL5095292 Extensive-stage small cell lung cancer GLRA2 2024-07-24 Tazemetostat N Y N N 2020 N DB12887 L01XX72 CHEMBL3414621 Locally Advanced Epithelioid Sarcoma; Metastatic Epithelioid Sarcoma SMARCB1; EZH2; ARID1A; FLT3; IDH1; SMARCA4; KDM6A 2024-07-24 Tebentafusp Y Y N N 2022 N DB15283 L01XX75 CHEMBL4297990 Metastatic Uveal Melanoma (UM), Unresectable Uveal Melanoma PMEL; TRBV20OR9-2; HLA-A; CD3G 2024-07-24 Teclistamab Y Y N N 2022 N DB16655 L01FX24 CHEMBL4594505 Multiple Myeloma CD3D; CD3E; CD3G; TNFRSF17 2024-07-24 Tegafur, Gimeracil, Oteracil Y N N N 2011 DB09256 L01BC03; L01BC53 CHEMBL20883 Advanced Gastric Cancer TYMP 2024-07-24 Tegafur, Uracil N N N Japan N DB09256 L01BC03; L01BC53 CHEMBL20883 Advanced Gastric Cancer TYMP 2024-07-24 Temoporfin Y N N N 2001 N DB11630 L01XD05 CHEMBL500576 Advanced Head and Neck Squamous Cell Carcinoma 2020-09-17 Temozolomide Y Y N N 1999 Y DB00853 L01AX03 CHEMBL810 Advanced Melanoma; Glioblastomas; Primary Central Nervous System Lymphoma (PCNSL); Refractory Ewing Sarcoma; Refractory Neuroblastoma; Soft Tissue Sarcoma (STS); Advanced Neuroendocrine tumor; Refractory Anaplastic astrocytoma; Refractory, advanced Mycosis fungoides; Refractory, advanced Sezary Syndrome PIK3CA; MGMT; HDAC4; PTEN; ATRX; TP53; MYC; IDH1; H2AX; BRCA2; GSTP1; CDKN2A; ATR; PRL; MSH6; CSF2; ALK; ARID1A; ATM; SLFN11 2024-07-24 Temsirolimus Y Y N N 2007 Y DB06287 L01EG01 CHEMBL1201182 Advanced Renal Cell Carcinoma NF2; VHL; PTEN; PIK3CA; MTOR; BRAF; FBXW7; RPTOR; FKBP1A; CTNNB1; KRAS; ETFB; PTPRD 2024-07-24 Tepotinib Y Y N N 2021 N DB15133 L01EX21 CHEMBL3402762 Metastatic Non-Small Cell Lung Cancer MET; EGFR; DRD4; ALK 2024-07-24 Thalidomide Y Y N Y 1998 N DB01041 L04AX02 CHEMBL468 Multiple Myeloma (MM); Waldenstrom's Macroglobulinemia (WM); Treatment naive multiple myeloma FCGR3B; FGFR2; DDB1; CRBN; F2R; RBX1; FCGR3A; TNF; CYP1A2; RPL13; ABCC6; NFKB1; SPG7; XRCC5; ATP7A; CYP4B1; VEGFA; SULT1C4; PTGS2; HLA-B; FGF2; VWF; CUL4A; CHST3; MECOM; NAT2; HGF; ERCC1; CTLA4; SLC10A2; CYP2C19; ITGB2; CTNNB1; IL6R; GSTT1; SNORD68; PPARD 2024-07-24 Thioguanine N Y N N 1966 N DB00352 L01BB03 CHEMBL727 Acute Nonlymphocytic Leukemia; Nonlymphocytic Acute myeloid leukemia KDM4A; CPT1A; GDA; GATA2; LINC00251; GGH; HPGD; IGHMBP2; MGMT; NUDT15; PNPLA3; EHMT2; UGT1A1; NAT1; PAX8; GATA3; BMP7; TPMT; XDH; NFE2L2; IMPDH1; PRPS1; ACHE; IMPDH2; NT5C2; DOK5; MYC; IDH1; HBB; SLC28A3; AR; TPM3; ABCC4 2024-07-24 Thiotepa Y Y N N 1959 Y DB04572 L01AC01 CHEMBL671 Adenocarcinoma of the Ovaries; Breast Adenocarcinoma; Papillary transitional cell carcinoma of bladder; Malignant effusion TP53; HPGD; GMNN; ALDH1A1; CYP2B6; EHMT2; VDR; GSTP1; ALDH3A1; AR 2024-07-24 Tisagenlecleucel Y Y N N 2017 N DB13881 L01XX71 CHEMBL3301574 Refractory B-cell precursor acute lymphoblastic leukemia; Second or later relapsed B-cell precursor acute lymphoblastic leukemia MS4A1; CD19 2024-07-24 Tislelizumab Y N N China N 2023 N DB14922 L01FF09 CHEMBL4297840 Unresectable, Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma GM2A 2024-07-25 Tisotumab Vedotin N Y N N 2021 N DB16732 L01FX23 CHEMBL4297841 Recurrent or metastatic cervical cancer TUBB1; F3; TUBA1B; TUBB8; TUBA3E; TUBB2A; TUBB6; TUBB2B; TUBA4A; TUBB; TUBA1C; TUBB4B; TUBA3C; TUBB3; TUBA1A; TUBB4A 2024-07-24 Tivozanib Y Y N N 2017 N DB11800 L01EK03 CHEMBL1289494 Advanced Renal Cell Carcinoma; Renal Cell Adenocarcinoma FLT4; BRAF; KDR; FLT1; NRAS; YES1; DRD1; DRD2; DRD3 2024-07-24 Topotecan Y Y N N 1996 Y DB01030 L01CE01 CHEMBL84 Acute Myeloid Leukemia (AML); Ewing's Sarcoma; Refractory Neuroblastoma; Metastatic Rhabdomyosarcoma; Recurrent, IV-B Cervical cancer; Refractory CNS lymphoma; Refractory CNS malignancy; Refractory, metastatic Ovarian cancer; Relapsed Small cell lung cancer DDO; PAX8; IDH1; ABCG2; AR; PLK1; TOP1; ALK; KMT2A; HIF1A; HBB; TSG101; ABCB1; AKT1; TYMS; RB1; TOP1MT; NFE2L2; MDM2; USP1; PTEN; TP53; PIK3CA; BDNF; MUC16 2024-07-24 Toremifene Y Y N N 1997 Y DB00539 L02BA02 CHEMBL1655 Desmoid Tumors; Metastatic Breast Cancer CYP1B1; ESR1; ESR2; CYP3A4; TGFB1; HNF4A; AR; CYP2D6; PGR; PLIN1; KDM4A; GMNN; CD80 2024-07-24 Toripalimab Y Y N N 2023 N DB15043 L01FF13 CHEMBL4297843 Metastatic and Recurrent Nasopharyngeal Carcinoma GM2A 2024-10-30 Tovorafenib N Y N N 2024 N DB15266 CHEMBL3348923 Relapsed or refractory pediatric low-grade glioma (LGG) harbouring a BRAF fusion or rearrangement, or BRAF V600 mutation RAF1; BRAF; ARAF; EFNA2; ZHX2 2024-07-24 Trabectedin Y Y N N 2015 N DB05109 L01CX01 CHEMBL450449 Metastatic Leiomyosarcoma; Metastatic Liposarcoma; Relapsed platinum-sensitive Ovarian cancer; Unresectable Leiomyosarcoma; Unresectable Liposarcoma PARP1; TP53; ABCC2; ABCB1; CD274; FGFR2 2024-07-24 Trametinib Y Y N N 2013 N DB08911 L01EE01 CHEMBL2103875 Metastatic Melanoma; Unresectable Melanoma; Metastatic Non-small cell lung cancer with a BRAF V600E mutation; Pediatric low-grade glioma (LGG) with a BRAF V600E mutation; Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation ETV5; BRAF; KRAS; FGFR1; MAP2K1; MAP2K2; TP53; NF1; PRKCH; RAF1; ABL1; ATM; MAP2K5; APC; ERBB3; G6PD; CDKN2A; KEAP1; ARAF; ETV4; RB1; ETV1; MET; VHL; MAP2K6; MAP2K4; DNMT3A; RET; KIT; MDM2; PIK3CA; EML4; PTEN; CD274; ATXN1L; NR2F6; ALK; MAP2K3; CIC; DDX43; RASA1; STK11; FLT3; HRAS; NRAS; CSF3R; CTNNB1; FGFR2; DUSP6; MAP2K7 2024-07-24 Trastuzumab Y Y N Y 1998 N DB00072 L01FD01 CHEMBL1201585 Breast Cancer; Early Breast Cancer; Inflammatory Breast Cancer (IBC); Locally Advanced Breast Cancer (LABC); Metastatic Adenocarcinoma of the Gastro-Esophageal Junction; Metastatic Adenocarcinoma of the Stomach; Metastatic Breast Cancer; Metastatic Gastric Adenocarcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma ERBB2 2024-07-24 Trastuzumab Deruxtecan Y Y N N 2019 N DB14962 L01FD04 CHEMBL4297844 HER2 Positive Breast Cancers ESR1; TOP1; ESR2; ERBB2 2024-07-24 Trastuzumab Emtansine Y Y N N 2013 N DB05773 L01FD03 CHEMBL1743082 Refractory, metastatic Non small cell lung cancer ERBB2; TUBA1B; TUBB2A; TUBA1C; TUBB1; TUBA4A; TUBA1A; TUBB6; TUBB4A; TUBB3; TUBB2B; TUBA3E; TUBB4B; TUBA3C; CD274; TUBB; PIK3CA; TUBB8 2024-07-24 Trastuzumab, Hyaluronidase Y Y N N 1998 N DB00072 L01XC03 CHEMBL1201585 Breast Cancer; Early Breast Cancer; Inflammatory Breast Cancer (IBC); Locally Advanced Breast Cancer (LABC); Metastatic Adenocarcinoma of the Gastro-Esophageal Junction; Metastatic Adenocarcinoma of the Stomach; Metastatic Breast Cancer; Metastatic Gastric Adenocarcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma ERBB2 2024-07-24 Tremelimumab Y Y N N 2022 N DB11771 L01FX20 CHEMBL2108658 Metastatic Non-Small Cell Lung Cancer, Unresectable Hepatocellular Carcinoma (HCC) CTLA4; MSH6; CD274; GLRB; PMS2; MLH1; ALK; EGFR; MSH2 2024-07-24 Tretinoin N Y Y N 1971 Y DB00755 D10AD01; L01XF01 CHEMBL38 FAB classification M3 Acute promyelocytic leukemia SFTPA1; RXRA; EHMT2; TGFBR3; RXRB; TBP; ALDH1A2; RARA; SMARCA4; SMAD2; NR2C1; HIF1A; P2RY2; AMH; SHH; NOS1; CDKN1B; PRL; THBS1; NPM1; TGFB1; TSPYL2; RARG; RET; HES1; MYOD1; BIRC5; IL1R1; BCKDHB; CEACAM1; RAB40B; NRIP1; CXCL8; RB1; XIAP; RARB; RXRG; SPP1; FLT3; MYCN; ERVK2; KLK3; BCHEL1; BCL2L2; BAX; WT1; TG; HOXB1; APOA1; ITGB2; NFE2L2; FAS; MDK; FUS; SLC2A1; PTPRZ1; CD55; TP73; VDR; HAS3; NR2C2; PTCH1; BHLHE40; RPE65; TPO; LIF; DUSP6; BCHE; BCL2; OCLN; CYP2C9; ALPL; KAT2A; HOXD1; IL10; USP1; RARRES1; NR2E1; CYP3A5; GLI1; PML; CALR; MAPK8; MST1; IFNG; EGR2; HSPA8; NR4A1; APOE; BCHEL3; ADH1C 2024-07-25 Trifluridine, Tipiracil Y Y N N 1980 Y DB00432 L01BC59; S01AD02 CHEMBL1129 Metastatic Colorectal Cancer (MCRC) ERBB2; SLC29A1; TP53 2024-02-07 Triptorelin N Y Y N 2000 N DB06825 L02AE04 CHEMBL1201334 Advanced Prostate Cancer GNRHR; STS 2024-07-24 Trofosfamide N N Y N DB12902 L01AA07 CHEMBL462019 Non-Hodgkin's lymphoma CYP2B6 2024-02-07 Tucatinib Y Y N N 2020 N DB11652 L01EH03 CHEMBL3989868 Breast Cancer; Unresectable Breast Cancer ERBB2; NRAS; HRAS; EN1; EGFR; DXO; KRAS; ERBB4 2024-07-24 Umbralisib N Y N N 2021 N DB14989 L01EX25 CHEMBL3948730 B-cell Follicular Lymphoma; Marginal Zone Lymphoma (MZL) PIK3CD; PIK3CG; ELF2; F7 2024-07-24 Valrubicin N Y N N 1998 Y DB00385 L01DB09 CHEMBL1096885 In situ BCG-refractory Bladder carcinoma TOP2A; AR 2024-02-07 Vandetanib Y Y N N 2011 N DB05294 L01EX04 CHEMBL24828 Metastatic Medullary Thyroid Cancer; Locally advanced Medullary thyroid cancer KDR; RET; PTEN; EGFR; LRRK2; ERBB4; FLT4; FLT1; ALK; FYN; MAP4K5; PDGFRB; GMNN; LCK; KRAS; EPHA1; SRC; EPHB1; EPHA3; TYRO3; AURKB; EPHB4; EPHB3; EPHA10; MAP2K2; IDH1; DRD2; BTK; ABL1; MAP2K1; PTK6; EPHB6; EPHA2; HTT; AXL; FGFR1; CYP3A4; APC; ROCK2; EPHB2; EPHA5; PTK2B; EPHA4; YES1; ERBB2; PDGFRA; DXO; TEK; MTOR; ERBB3; MAPK14; MAP4K4; ATM; LTK; EPHA6; EPHA7; ACVR1; EPHA8 2024-07-24 Vemurafenib Y Y N N 2011 N DB08881 L01EC01 CHEMBL1229517 Metastatic Melanoma; Unresectable Melanoma; Refractory Non-small cell lung cancer CDKN2A; NRAS; PIK3CA; MITF; PTEN; RB1; MET; PIK3R2; RAC1; BRAF; PREX2; HRAS; NF1; CYP3A4; TET2; MAP2K1; ATXN1L; EFNA2; TP53; KEAP1; CBL; CIC; FGFR2; KRAS; ABCB1; STAG3; YES1; FAH; MAP2K2; CYP1A2; CYP3A; TF; STAG2; SOX10; AKT1; AKT3 2024-07-24 Venetoclax Y Y N N 2016 N DB11581 L01XX52 CHEMBL3137309 Chronic Lymphocytic Leukaemia (CLL); Small Lymphocytic Lymphoma IGH; BCL2; LPAR4; ALK; IDH2; KDM6A; NPM1; FLT3; GPR21; GPR22; BRAF; TP53; KMT2A; NRAS; PIK3CA; KIT; PTEN; ATM; MCHR1; ABL1; IDH1 2024-07-24 Vinblastine N Y Y Y 1965 Y DB00570 L01CA01 CHEMBL159 Advanced Soft Tissue Sarcoma; Cancer, Bladder; Kaposi's sarcoma; Lymphoma, Hodgkins; Metastatic Melanoma; Non-Small Cell Lung Carcinoma (NSCLC); Advanced Alibert-Bazin syndrome; Advanced Testicular cancer; Histiocytic lymphoma; Refractory Breast cancer TUBA3D; TUBB8; TBXA2R; CDKN1A; TUBB4A; TUBA3C; TUBA3E; PTHLH; NR1I2; TUBB6; CGA; TUBA1A; TUBB4B; ABCB1; CSF2; TUBA4A; TUBA1C; NOP2; TUBB2A; CYP3A4; TUBB3; KLK3; NF1; GCF1; TRH; TUBB1; ABCB4; GMNN; TUBA1B; BRAF; TUBB2B; TUBB; MMP2; GSTM1 2024-07-24 Vincristine N Y Y Y 1965 Y DB00541 L01CA02 CHEMBL90555 Acute Lymphoblastic Leukaemia Recurrent; Acute Lymphocytic Leukemia (ALL); Choriocarcinoma; Chronic Lymphocytic Leukaemia (CLL); Ewing's Sarcoma; Hepatoblastomas; Kaposi's sarcoma; Lymphoma, Hodgkins; Multiple Myeloma (MM); Neuroblastomas; Non-Hodgkin's Lymphoma (NHL); Ovarian germ cell tumour; Pheochromocytomas; Retinoblastoma; Rhabdomyosarcomas; Small Cell Lung Cancer (SCLC); Wilms' tumor; Advanced Thymoma NKAIN3; STIM1; TUBB4B; MIR4268; CP; TUBB2A; SULF2; GATA3; HSPB2; TUBB6; BCL2; MIR4481; ABCC1; TYMS; PIK3CG; BCR; SRI; TUBA4A; CDKN1B; CAPG; NRG1; MIR6076; NOS3; MIR3117; UGT1A1; TP73; TUBB1; ABL1; TUBB8; BAHD1; FGF2; TUBB3; MRPL47; FCGR3A; SMAD3; TUBA3C; ATF5; AFP; TUBA1B; TUBA3D; MTR; CPT1A; TOP2A; IGHMBP2; TUBA1A; XDH; NR1I2; TUBB4A; DOK5; COCH; RAC2; BMP7; AR; TPMT; ABCB4; CXCL12; NTF3; ABCC10; TUBA3E; NCF4; ABCB1; ODC1; TUBB2B; TUBA1C; PIK3CA; SYNE2; LINC00251; ACTG1; MTHFR; GSTA1; GCF1; BDNF; TUBB; MYCN; ABCC3; VWF; PNPLA3; RALBP1; SLC5A7; GMNN; CYBA 2024-07-24 Vincristine Liposome N Y N N 2012 Y DB00541 L01CA02 CHEMBL501867 Acute Lymphoblastic Leukaemia Recurrent; Acute Lymphocytic Leukemia (ALL); Choriocarcinoma; Chronic Lymphocytic Leukaemia (CLL); Ewing's Sarcoma; Hepatoblastomas; Kaposi's sarcoma; Lymphoma, Hodgkins; Multiple Myeloma (MM); Neuroblastomas; Non-Hodgkin's Lymphoma (NHL); Ovarian germ cell tumour; Pheochromocytomas; Retinoblastoma; Rhabdomyosarcomas; Small Cell Lung Cancer (SCLC); Wilms' tumor; Advanced Thymoma TUBB6; TUBB3; TUBA3C; ALK; TUBB4A; GMNN; TUBB8; TUBB4B; TUBB2B; TUBA1A; TUBB1; TUBB; TUBA4A; HIF1A; TUBA3E; TUBA1C; NR0B1; TUBA1B; TUBB2A 2024-07-24 Vindesine N N Y N 1979 N DB00309 L01CA03 CHEMBL238071 Acute Lymphocytic Leukemia (ALL); Melanoma, Malignant TUBB; ABCB1; TUBB1; CYP3A4 2024-07-24 Vinflunine Y N N N 2009 N DB11641 L01CA05 CHEMBL2110725 Transitional Cell Carcinoma of the Urothelial Tract; Metastatic Transitional Cell Carcinoma of the Urothelial Tract TUBB2B; TUBA1A; TUBB; TUBB4A; TUBB1; TUBA4A; TUBB2A; TUBA3C; TUBA1B; TUBA1C; TUBB6; TUBA3E; TUBB3; TUBB8; TUBB4B 2024-07-24 Vinorelbine N Y Y Y 1994 Y DB00361 L01CA04 CHEMBL553025 Advanced Non Small Cell Lung Cancer; Esophageal Cancers; Locally Advanced Non-Small Cell Lung Cancer; Metastatic Breast Cancer; Recurrent Cervical Cancer; Soft Tissue Sarcoma (STS); Recurrent, IV-B Cervical cancer TUBA3E; TUBA3D; TUBA4A; TUBB2A; APC; TUBA1A; TUBB4A; TUBB4B; STMN1; BAX; RRM1; TUBA3C; CSF2; TUBA1B; SMARCA4; XRCC1; TUBB3; TUBB1; TUB; BRCA1; TUBB6; TUBB; TUBA1C; TUBB2B; MTHFR; TUBB8 2024-07-24 Vismodegib Y Y N N 2012 N DB08828 L01XJ01 CHEMBL473417 Locally Advanced Basal Cell Carcinoma; Metastatic Basal cell carcinoma SMO; PTCH1; SHH; ALOX12 2024-07-24 Vorasidenib N Y N N 2024 DB17097 L01XM04 CHEMBL4279047 Grade 2 astrocytoma or oligodendroglioma IDH1; IDH2; GRB2; GPX1P2 2024-11-28 Vorinostat N Y N N 2006 N DB02546 L01XH01 CHEMBL98 Persistent Cutaneous T-Cell Lymphoma; Progressive Cutaneous T-cell lymphoma; Recurrent Cutaneous T-cell lymphoma TUBA1C; TUBA3D; IDH1; PAX8; TUBB4A; TUBB4B; GAS1; GAPDHP1; HDAC9; TUBB2A; TUBB8; HDAC6; BRAF; NR0B1; HDAC7; HDAC2; GART; HDAC8; GAPDHL17; HDAC11; HDAC4; GAS2; HDAC5; BIRC5; HDAC1; CFTR; TUBA3C; HDAC3; GDF2; GARS1; MYC; TP53; TUBA1A; TUBA3E; CHD4; MSTN; TUBB2B; UGT2B17; TUBA1B; TUBB6; TUBB1; LRRC32; BAP1; GMNN; TUBB3; ERBB2; FBXW7; NFE2L2; ACE; GNA11; HDAC10; TUBB; PTEN; RB1; TUBA4A 2024-07-24 Zanubrutinib Y Y N N 2019 N DB15035 L01EL03 CHEMBL3936761 Mantle Cell Lymphoma (MCL) TP53; BTK; EFNB2; MYD88 2024-07-24 Zolbetuximab Y Y N N 2024 DB15118 L01FX31 CHEMBL2109427 Locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma GRIN2A 2024-11-28